BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

```
ID   AE001587   standard; DNA; PRO; 16448 BP.
XX
AC   AE001587; AE001363;
XX
SV   AE001587.1
XX
DT   15-MAR-1999 (Rel. 59, Created)
DT   02-SEP-2002 (Rel. 72, Last updated, Version 5)
XX
DE   Chlamydia pneumoniae section 3 of 103 of the complete genome.
XX
KW   .
XX
OS   Chlamydophila pneumoniae CWL029
OC   Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydophila;
OC   Chlamydophila pneumoniae.
XX
RN   [1]
RP   1-16448
RX   MEDLINE; 99206606.
RX   PUBMED; 10192388.
RA   Kalman S., Mitchell W., Marathe R., Lammel C., Fan J., Hyman R.W.,
RA   Olinger L., Grimwood J., Davis R.W., Stephens R.S.;
RT   "Comparative genomes of Chlamydia pneumoniae and C. trachomatis";
RL   Nat. Genet. 21(4):385-389(1999).
XX
RN   [2]
RP   1-16448
RA   Kalman S., Mitchell W., Marathe R., Lammel C., Fan J., Olinger L.,
RA   Grimwood J., Davis R.W., Stephens R.S.;
RT   ;
RL   Submitted (01-DEC-1998) to the RL   Program in Infectious Diseases, University o
RL   Hall, Berkeley, CA 94720, USA
XX
DR   SPTREMBL; Q9Z9F7; Q9Z9F7.
DR   SPTREMBL; Q9Z9F8; Q9Z9F8.
DR   SPTREMBL; Q9Z9G0; Q9Z9G0.
DR   SPTREMBL; Q9Z9G1; Q9Z9G1.
DR   SWISS-PROT; Q9Z9F9; Y022_CHLPN.
XX
FH   Key             Location/Qualifiers
FH
FT   source          1..16448
FT                   /db_xref="taxon:115713"
FT                   /organism="Chlamydophila pneumoniae CWL029"
FT                   /strain="CWL029"
FT   misc_feature    172..2957
FT                   /note="Polymorphic Outer Membrane Protein G Family;
FT                   contains frame shift"
FT   misc_feature    3196..5953
FT                   /note="Polymorphic Outer Membrane Protein G Family;
FT                   contains frame shift"
FT   misc_feature    6302..9139
FT                   /note="Polymorphic Outer Membrane Protein G Family;
FT                   contains frame shift"
FT   CDS             complement(9380..11467)
FT                   /codon_start=1
FT                   /db_xref="SPTREMBL:Q9Z9G1"
FT                   /transl_table=11
FT                   /gene="CPn0020"
```

```
FT                   /product="Predicted OMP [leader peptide: outer membrane]"
FT                   /protein_id="AAD18173.1"
FT                   /translation="MKRCFLFLASFVLMGSSADALTHQEAVKKKNSYLSHFKSVSGIVT
FT                   IEDGVLNIHNNLRIQANKVYVENTVGQSLKLVAHGNVMVNYRAKTLVCDYLEYYEDTDS
FT                   CLLTNGRFAMYPWFLGGSMITLTPETIVIRKGYISTSEGPKKDLCLSGDYLEYSSDSLL
FT                   SIGKTTLRVCRIPILFLPPFSIMPMEIPKPPINFRGGTGGFLGSYLGMSYSPISRKHFS
FT                   STFFLDSFFKHGVGMGFNLHCSQKQVPENVFNMKSYYAHRLAIDMAEAHDRYRLHGDFC
FT                   FTHKHVNFSGEYHLSDSWETVADIFPNNFMLKNTGPTRVDCTWNDNYFEGYLTSSVKVN
FT                   SFQNANQELPYLTLRQYPISIYNTGVYLENIVECGYLNFAFSDHIVGENFSSLRLAARP
FT                   KLHKTVPLPIGTLSSTLGSSLIYYSDVPEISSRHSQLSAKLQLDYRFLLHKSYIQRRHI
FT                   IEPFVTFITETRPLAKNEDHYIFSIQDAFHSLNLLKAGIDTSVLSKTNPRFPRIHAKLW
FT                   TTHILSNTESKPTFPKTACELSLPFGKKNTVSLDAEWIWKKHCWDHMNIRWEWIGNDNV
FT                   AMTLESLHRSKYSLIKCDRENFILDVSRPIDQLLDSPLSDHRNLILGKLFVRPHPCWNY
FT                   RLSLRYGWHRQDTPNYLEYQMILGTKIFEHWQLYGVYERREADSRFFFFLKLDKPKKPP
FT                   F"
FT   CDS             complement(11484..13190)
FT                   /codon_start=1
FT                   /db_xref="SPTREMBL:Q9Z9G0"
FT                   /transl_table=11
FT                   /gene="CPn0021"
FT                   /product="Predicted OMP [leader peptide]"
FT                   /protein_id="AAD18174.1"
FT                   /translation="MGLFHLTLFGLLLCSLPISLVAKFPESVGHKILYISTQSTQQALA
FT                   TYLEALDAYGDHDFFVLRKIGEDYLKQSIHSSDPQTRKSTIIGAGLAGSSEALDVLSQA
FT                   METADPLQQLLVLSAVSGHLGKTSDDLLFKALASPYPVIRLEAAYRLANLKNTKVIDHL
FT                   HSFIHKLPEEIQCLSAAIFLRLETEESDAYIRDLLAAKKSAIRSATALQIGEYQQKRFL
FT                   PTLRNLLTSASPQDQEAILYALGKLKDGQSYYNIKKQLQKPDVDVTLAAAQALIALGKE
FT                   EDALPVIKKQALEERPRALYALRHLPSEIGIPIALPIFLKTKNSEAKLNVALALLELGC
FT                   DTPKLLEYITERLVQPHYNETLALSFSKGRTLQNWKRVNIIVPQDPQERERLLSTTRGL
FT                   EEQILTFLFRLPKEAYLPCIYKLLASQKTQLATTAISFLSHTSHQEALDLLFQAAKLPG
FT                   EPIIRAYADLAIYNLTKDPEKKRSLHDYAKKLIQETLLFVDTENQRPHPSMPYLRYQVT
FT                   PESRTKLMLDILETLATSKSSEDIRLLIQLMTEGDAKNFPVLAGLLIKIVE"
FT   CDS             complement(13172..13762)
FT                   /codon_start=1
FT                   /db_xref="SWISS-PROT:Q9Z9F9"
FT                   /transl_table=11
FT                   /gene="maf"
FT                   /product="Maf-type protein"
FT                   /protein_id="AAD18175.1"
FT                   /translation="MSLPLVLGSSSPRRKFILEKFRVPFTVIPSNFDESKVSYSGDPIA
FT                   YTQELAAQKAYAVSELHSPCDCIILTGDTIVSYDGRIFTKPQDKADAIQMLKTLRNQTH
FT                   DVVTSIAVLHKGKLLTGSETSQISLTMIPDHRIESYIDTVGTLNNCGAYDVCHGGLILK
FT                   KVHGCVYNVQGLPIQTLKYLLEELNIDLWDYSI"
FT   CDS             complement(13791..15383)
FT                   /codon_start=1
FT                   /db_xref="SPTREMBL:Q9Z9F8"
FT                   /transl_table=11
FT                   /gene="yjjK"
FT                   /product="ABC Transporter Protein ATPase"
FT                   /protein_id="AAD18176.1"
FT                   /translation="MSIVLDKIGKSLGTRILFDDVSVVFNPGNCYGLTGPNGAGKSTLL
FT                   KIIMGMIEPTRGSISLPKKVGILRQNIDSFHDTTVLDCVIMGNTRLWEALQRRDNLYLQ
FT                   EFTDAIGMELGEIEEIIGEENGYRADSEAEELLTGIGIPNEMFDKKMAMIPIDLQFRVL
FT                   LCQALFGHPEALLLDEPTNHLDLYSINWLGNFLKDYEGTVIVVSHDRHFLNTITTHIAD
FT                   IDYDTIIIYPGNYDDMVEMKTASREQEKADIKSKEKKISQLKEFVAKFGAGSRASQVQS
FT                   RLREIKKLQPQELKKSNIQRPYIRFPLSDKSSGKVVLSLEAITKDYGDHQVIHPFSLEI
FT                   YQGDKLGIIGNNGLGKTTLMKLLAGVEAPSSGSIKLGHQAICSYFPQNHSDVLADCGQE
FT                   TLFEWLRNRKTGINDQEIRSVLGKMLFGGDDAFKQIQALSGGETARLLMAGMMLENHNV
FT                   LILDEANNHLDLESVSALSWAINDYKGTAIFVSHDRGLIQDCATKLLIFDKDKITFFDG
FT                   TMVDYTAGHKQLL"
```

```
FT   CDS             complement(15438..16376)
FT                   /codon_start=1
FT                   /db_xref="SPTREMBL:Q9Z9F7"
FT                   /transl_table=11
FT                   /gene="xerC"
FT                   /product="Integrase/recombinase"
FT                   /protein_id="AAD18177.1"
FT                   /translation="MIASIYSFLDYLKMVKSASPHTLRNYCLDLNGLKIFLEERGNLAP
FT                   SSPLQLATEKRKVSELPFSLFTKEHVRMYIAKLIENGKAKRTIKRCLSSIKSFAHYCVI
FT                   QKILLENPAETIHGPRLPKELPSPMTYAQVEVLMATPDISKYHGLRDRCLMELFYSSGL
FT                   RISEIVAVNKQDFDLSTHLIRIRGKGKKERIIPVTSNAIQWIQIYLNHPDRKRLEKDPQ
FT                   AIFLNRFGRRISTRSIDRSFQEYLRRSGLSGHITPHTIRHTIATHWLESGMDLKTIQAL
FT                   LGHSSLETTTVYTQVSVKLKKQTHQEAHPHA"
XX
SQ   Sequence 16448 BP; 4710 A; 3330 C; 3665 G; 4743 T; 0 other;
     tgatccctca aaatcacatt ttggtatctg attgctaaga ttgcaggata ccacgcatct        60
     taagagaaag gcgctcttac ctagtagagg ttgagtgaat ttcttgactt gtttctccta       120
     ttggtgtatc tcttaaaata ttaaattcaa aatcaaagta tatattttac aatgaagtct       180
     tctttcccca agtttgtatt ttctacattt gctattttcc ctttgtctat gattgctacc       240
     gagacagttt tggattcaag tgcgagtttc gatgggaata aaaatggtaa tttttcagtt       300
     cgtgagagtc aggaagatgc tggaactacc tacctattta agggaaatgt cactctagaa       360
     aatattcctg gaacaggcac agcaatcaca aaaagctgtt ttaacaacac taagggcgat       420
     ttgactttca caggtaacgg gaactctcta ttgttccaaa cggtggatgc agggactgta       480
     gcaggggctg ctgttaacag cagcgtggta gataaatcta ccacgtttat agggttttct       540
     tcgctatctt ttattgcgtc tcctggaagt tcgataacta ccggcaaagg agccgttagc       600
     tgctctacgg gtagcttgag tttgacaaaa atgtcagttt gctcttcagc aaaaactttt       660
     caacggataa tggcggtgct atcaccgcaa aaactctttc attaacaggg actacaatgt       720
     cagctctgtt ttctgaaaat acctcctcaa agaaaggcgg agccattcag acttccgatg       780
     cccttaccat tactggaaac caaggggaag tctcttttc tgacaatact tcttcggatt       840
     ctggagctgc aatttttaca gaagcctcgg tgactatttc taataatgct aaagtttcct       900
     ttattgacaa taaggtcaca ggagcgagct cctcaacaac gggggatatg tcaggaggtg       960
     ctatctgtgc ttataaaact agtacagata ctaaggtcac cctcactgga aatcagatgt      1020
     tactcttcag caacaataca tcgacaacag cgggaggagc tatctatgtg aaaaagctcg      1080
     aactggcttc cggaggactt accctattca gtagaaatag tgtcaatgga ggtacagctc      1140
     ctaaaggtgg agccatagct atcgaagata gtggggaatt gagtttatcc gccgatagtg      1200
     gtgacattgt ctttttaggg aatacagtca cttctactac tcctgggacg aatagaagta      1260
     gtatcgactt aggaacgagt gcaaagatga cagctttgcg ttctgctgct ggtagagcca      1320
     tctacttcta tgatcccata actacaggat catccacaac agttacagat gtcttaaaag      1380
     ttaatgagac tccggcagat tctgcactac aatatacagg gaacatcatc ttcacaggag      1440
     aaaagttatc agagacagag gccgcagatt ctaaaaatct tacttcgaag ctactacagc      1500
     ctgtaactct ttcaggaggt actctatctt taaaacatgg agtgactctg cagactcagg      1560
     cattcactca acaggcagat tctcgtctcg aaatggacgt aggaactact ctagaacctg      1620
     ctgatactag caccataaac aatttggtca ttaacatcag ttctatagac ggtgcaaaga      1680
     aggcaaaaat agaaaccaaa gctacgtcaa aaaatctgac tttatctgga accatcactt      1740
     tattggaccc gacgggcacg ttttatgaaa atcatagttt aagaaatcct cagtcctacg      1800
     acatcttaga gctcaaagct tctggaactg taacaagcac cgcagtgact ccagatccta      1860
     taatgggtga gaaattccat tacggctatc agggaacttg gggcccaatt gtttggggga      1920
     caggggcttc tacgactgca accttcaact ggactaaaac tggctatatt cctaatcccg      1980
     agcgtatcgg ctctttagtc cctaatagct tatggaatgc atttatagat attagctctc      2040
     tccattatct tatggagact gcaaacgaag ggttgcaggg agaccgtgct ttttggtgtg      2100
     ctggattatc taacttcttc cataaggata gtacaaaaac acgacgcggg tttcgccatt      2160
     tgagtggcgg ttatgtcata ggaggaaacc tacatacttg ttcagataag attcttagtg      2220
     ctgcattttg tcagctcttt ggaagagata gagactactt tgtagctaag aatcaaggta      2280
     cagtctacgg aggaactctc tattaccagc acaacgaaac ctatatctct cttccttgca      2340
     aactacggcc ttgttcgttg tcttatgttc ctacagagat tcctgttctc ttttcaggaa      2400
     accttagcta cacccatacg gataacgatc tgaaaaccaa gtatacaaca tatcctactg      2460
     ttaaaggaag ctgggggaat gatagtttcg ctttagaatt cggtggaaga gctccgattt      2520
     gcttagatga aagtgctcta tttgagcagt acatgccctt catgaaattg cagtttgtct      2580
     atgcacatca ggaaggtttt aaagaacagg gaacagaagc tcgtgaattt ggaagtagcc      2640
     gtcttgtgaa tcttgcctta cctatcggga tccgatttga taaggaatca gactgccaag      2700
```

```
atgcaacgta caatctaact cttggttata ctgtggatct tgttcgtagt aaccccgact  2760
gtacgacaac actgcgaatt agcggtgatt cttggaaaac cttcggtacg aatttggcaa  2820
gacaagcttt agtccttcgt gcagggaacc atttttgctt taactcaaat tttgaagcct  2880
ttagccaatt ttcttttgaa ttgcgtgggt catctcgcaa ttacaatgta gacttaggag  2940
caaaatacca attctaatgc gttagctttg gtaaagagct ccatacatcg aagggaaaag  3000
agcttttaag atttcttgaa ggctcttttc gatttcgatt tccattttag tgttttgcta  3060
aaacactttc taatttttt cttttgtttt ctacattgaa aaaaagagag ttacggcagc  3120
tgtaaagttt ttaatattgc tccctttgtt ccatttatgt agcgttcaga ctttgcacta  3180
aaacgagggt gtcatatgag atcgtctttt tccttgttat taatatcttc atctctagcc  3240
tttcctctct taatgagtgt ttctgcagat gctgccgatc tcacattagg gagtcgtgac  3300
agttataatg gtgatacaag caccacagaa tttactccta aagcggcaac ttctgatgct  3360
agtggcacga cctatattct cgatggggat gtctcgataa gccaagcagg gaaacaaacg  3420
agcttaacca caagttgttt ttctaacact gcaggaaatc ttaccttctt agggaacgga  3480
ttttctcttc attttgacaa tattatttcg tctactgttg caggtgttgt tgttagcaat  3540
acagcagctt ctgggattac gaaattctca ggattttcaa ctcttcggat gcttgcagct  3600
cctaggacca caggtaaagg agccattaaa attaccgatg gtctggtgtt tgagagtata  3660
gggaatcttg atcttaatga aaatgcctct agtgaaaatg ggggagccat caatacgaag  3720
actttgtctt tgactgggag tacgcggttt gtagcgttcc ttggcaatag ctcgtcgcaa  3780
caaggggggag cgatctatgc ttctggtgac tctgtgattt ctgagaatgc aggaatcttg  3840
agcttcggaa acaacagtgc gacaacatca ggaggcgcga tctctgctga agggaacctt  3900
gtgatctcca ataaccaaaa tatctttttc gatggctgca aagcaactac aaatggcgga  3960
gctattgatt gtaacaaagc aggggcgaac ccagacccta tcttgactct ttcaggaaat  4020
gagagcctgc attttctgaa taacacagca ggaaatagtg gaggtgcgat ttataccaaa  4080
aaattggtgt tatcctcagg acgaggagga gtgttatttt ctaacaacaa agctgcgaat  4140
gctactccta aaggaggggc aattgcgatt ctagattctg gagagattag catttctgca  4200
gatctcggca atatcatttt cgagggcaat actacgagca ctacaggaag tcctgcgagt  4260
gtgaccagaa atgctataga tcttgcatcg aatgcaaaat ttttaaatct ccgagcgact  4320
cggggaaata aagttatttt ctatgatcct atcacgagct caggagctac tgataagctc  4380
tctttgaata aagctgacgc aggatctgga aatacctatg aaggctacat cgttttctct  4440
ggagagaaac tctcagaaga ggaacttaag aaacctgaca atctgaagtc tacatttaca  4500
caggctgtag agcttgctgc aggtgcctta gtattgaaag atggagtgac tgtagttgca  4560
aatactataa cgcaggtcga gggatcgaaa gtcgttatgg atggagggac tacttttgag  4620
gcaagcgctg agggggtcac tctcaatggc ctagccatta atatagattc cttagatggg  4680
acaaataaag ctatcattaa ggcgacggca gcaagtaagg atgttgcctt atcagggcct  4740
atcatgcttg tagatgctca ggggaactat tatgagcatc ataatctcag tcaacagcag  4800
gtctttcctt taatagagct ttctgcacaa ggaacgatga ctactacaga tatccccgat  4860
accccaattc taaatactac gaatcactat gggtatcaag ggaactggaa taattgtttg  4920
ggtcgacgat gcaactgcaa aaacaaaaaa tgctacctta acttggacta aaacaggata  4980
caagccgaat ccagaacgtc agggaccttt ggttcctaat agcctgtggg gttcttttgt  5040
cgatgtccgc tccattcaga gcctcatgga ccggagcaca agttcgttat cttcgtcaac  5100
aaatttgtgg gtatcaggaa tcgcggactt tttgcatgaa gatcagaaag gaaaccaacg  5160
tagttatcgt cattctagcg cgggttatgc attaggagga ggattcttca cggcttctga  5220
aaatttcttt aattttgctt tttgtcagct ttttggctac gacaaggacc atcttgtggc  5280
taagaaccat acccatgtat atgcaggggc aatgagttac cgacacctcg gagagtctaa  5340
gaccctcgct aagattttgt caggaaattc tgactcccta ccttttgtct tcaatgctcg  5400
gtttgcttat ggccataccg acaataacat gaccacaaag tacactggct attctcctgt  5460
taagggaagc tggggaaatg atgccttcgg tatagaatgt ggaggagcta tcccggtagt  5520
tgcttcagga cgtcggtctt gggtggatac ccacacgcca tttctaaacc tagagatgat  5580
ctatgcacat cagaatgact ttaaggaaaa cggcacagaa ggccgttctt tccaaagtga  5640
agacctcttc aatctagcgg ttcctgtagg gataaaattt gagaaattct ccgataagtc  5700
tacgtatgat ctctccatag cttacgttcc cgatgtgatt cgtaatgatc caggctgcac  5760
gacaactctt atggtttctg gggattcttg gtcgacatgt ggtacaagct tgtctagaca  5820
agctcttctt gtacgtgctg gaaatcatca tgcctttgct tcaaactttg aagttttcag  5880
tcagtttgaa gtcgagttgc gaggttcttc tcgtagctat gctatcgatc ttggaggaag  5940
attcggattt taatcctaag ttttccaacg agatagcatc agggtaagcc agggctctat  6000
gtaagagatt tcatagagcc ctctctttgt cttgcttttt gtattttatt tttatatttc  6060
gtgaatccgt tgttccaatg ttcgaaaggt atcctagatg agattgctgt tgtcttgtcc  6120
tatgcttttt atagctgcat gtgcctcatt ttttggcttt caggaagaaa tgcaaggcag  6180
aaatatacaa tctcttgatg caaatgcttc tagtctaggg gaacttttt ctatttctac  6240
gaagggagtg tcttgtctag aactccatag ggagatcgca cgctaaatat gagaatataa  6300
```

```
tatgaagact tcagtttcta tgttgttggc cctgctttgc tcgggggcta gctctattgt      6360
actccatgcc gcaaccactc cactaaatcc tgaagatggg tttattgggg agggcaatac      6420
aaatactttt tctccgaaat ctacaacgga tgctgcagga actacctact ctctcacagg      6480
agaggttctg tatatagatc cggggaaagg tggttcaatt acaggaactt gctttgtaga      6540
aactgctggc gatcttacat ttttaggtaa tggaaatacc ctaaagttcc tgtcggtaga      6600
tgcaggtgct aatatcgcgg ttgctcatgt acaaggaagt aagaatttaa gcttcacaga      6660
tttccttttct ctggtgatca cagaatctcc aaaatccgct gttactacag gaaaaggtag      6720
cctagtcagt ttaggtgcag tccaactgca agatataaac actctagttc ttacaagcaa      6780
tgcctctgtc gaagatggtg gcgtgattaa aggaaactcc tgcttgattc agggaatcaa      6840
aaatagtgcg atttttggac aaaatacatc ttcgaaaaaa ggaggggcga tctccacgac      6900
tcaaggactt accatagaga ataacttagg gacgctaaag ttcaatgaaa acaaagcagt      6960
gacctcagga ggcgccttag atttaggagc cgcgtctaca ttcactgcga accatgagtt      7020
gatattttca caaaataaga cttctgggaa tgctgcaaat ggcggagcca taaattgctc      7080
aggggacctt acatttactg ataacacttc tttgttactt caagaaaata gcacaatgca      7140
ggatggtgga gctttgtgta gcacaggaac cataagcatt accggtagtg attctatcaa      7200
tgtgatagga aatacttcag gacaaaaagg aggagcgatt tctgcagctt ctctcaagat      7260
tttgggaggg cagggaggcg ctctcttttc taataacgta gtgactcatg ccacccctct      7320
aggaggtgcc atttttatca acacaggagg atccttgcag ctcttcactc aaggagggga      7380
tatcgtattc gaggggaatc aggtcactac aacagctcca aatgctacca ctaagagaaa      7440
tgtaattcac ctcgagagca ccgcgaagtg gacgggactt gctgcaagtc aaggtaacgc      7500
tatctatttc tatgatccca ttaccaccaa cgatacggga gcaagcgata acttacgtat      7560
caatgaggtc agtgcaaatc aaaagctctc gggatctata gtattttctg gagagagatt      7620
gtcgacagca gaagctatag ctgaaaatct tacttcgagg atcaaccagc ctgtcacttt      7680
agtagagggg agcttagtac ttaaacaggg agtgaccttg atcacacaag gattctcgca      7740
ggagccagaa tccacgcttc ttttggatct ggggacctca ttataagctt ctacagaaga      7800
tattgtcatc acaaatttat ctataaatgc cgataccatt tacggaaaga atcctatcaa      7860
tattgtagct tcagcagcga ataagaacat taccctaaca ggaaccttag cacttgtaaa      7920
tgcagatgga gctttctatg agaaccatac cttgcaagac tctcaagact atagctttgt      7980
aaagttatct ccaggagcgg gagggactat aattactcaa gatgcttctc agaagcctct      8040
tgaagtagct ccttctagac cacattatgg ctatcaagga cattggaatg tgcaagtcat      8100
cccaggaacg ggaactcaac cgagccaggc aaatttagaa tgggtgcgga caggatacct      8160
tccgaatccc gaacggcaag gatctttagt tcccaatagc ctgtggggtt cttttgttga      8220
tcagcgtgct atccaagaaa tcatggtaaa tagtagccaa atcttatgtc aggaacgggg      8280
agtctgggga gctggaattg ctaatttcct acatagagat aaaattaatg agcacggcta      8340
tcgccatagc ggtgtcggtt atcttgtggg agttggcact catgcttttt ctgatgctac      8400
gataaatgcg gctttttgcc agctcttcag tagagataaa gactacgtag tatccaaaaa      8460
tcatggaact agctactcag gggtcgtatt tcttgaggat accctagagt ttagaagtcc      8520
acagggattc tatactgata gctcctcaga agcttgctgt aaccaagtcg tcactataga      8580
tatgcagttg tcttacagcc atagaaataa tgatatgaaa accaaataca cgacatatcc      8640
agaagctcag ggatcttggg caaatgatgt ttttggtctt gagtttggag cgactacata      8700
ctactaccct aacagtactt ttttatttga ttactactct ccgtttctca ggctgcagtg      8760
cacctatgct caccaggaag acttcaaaga gacaggaggt gaggttcgtc actttactag      8820
cggagatctt ttcaatttag cagttcctat tggcgtgaag tttgagagat tttcagactg      8880
taaaagggga tcttatgaac ttacccttgc ttatgttcct gatgtgattc gcaaagatcc      8940
caagagcacg gcaacattgg ctagtggagc tacgtggagc acccacggaa acaatctctc      9000
cagacaagga ttacaactgc gtttagggaa ccactgtctc ataaatcctg gaattgaggt      9060
gttcagtcac ggagctattg aattgcgggg atcctctcgt aattataaca tcaatctcgg      9120
gggtaaatac cgattttaat agggaactga gagttcctta ttgtagagag tatttacaag      9180
gattttgaga cgaaagagat ttcttgttgt aggtatctct ccacagggtc tagttcaatt      9240
tctatagttc atggggtttc tttttttata aagaagaaac cccatgtctg acgagacctc      9300
acctggatct attgcattct ctatggtaag ggatccatga cttgacacag gaggttcatt      9360
ctcatgtcta agtcagaggt tagaagggag gtttttttagg tttgtcgagc tttaagaaga      9420
agaaaaatcg actatctgct tctcggcgtt catacacccc atagagctgc caatgttcga      9480
agatcttcgt ccctagaatc atctggtatt ctaggtagtt cggagtgtcc tggcgatgcc      9540
agccatagcg taaggataag cggtaattcc aacagggatg aggtcgtaca aataatttcc      9600
ctaaaatgag attcctatga tcagagagag gggagtctaa aagctggtca atgggacggc      9660
tgacatctaa aatgaagttc tccctgtcac acttaatcag gctgtatttg cttctatgca      9720
gggattctag agtcatagcc acattgtcat ttccgatcca ctcccaacgt atgttcatgt      9780
gatcccaaca gtgctttttc caaatccatt cagcatctaa ggagactgta tttttctttc      9840
caaaaggtag agatagctcg catgcagttt tgggaaacgt gggtttgctt tctgtattgc      9900
```

```
tcaagatgtg ggtagtccac agcttcgcat ggattctcgg gaatcgaggg ttagtcttac      9960
tcagtaccga ggtatctata cccgctttca gaaggtttaa ggagtgaaag gcatcttgaa     10020
tagaaaagat ataatgatct tcattcttag ctagaggacg agtctctgta atgaaggtaa     10080
cgaacggctc tataatatgg cgtctttgaa tgtaggactt atgtaataga aagcgataat     10140
caagttgtag cttcgcggaa agctgactat ggcgcgagga gatctcagga acatcgctat     10200
agtaaatcag agaactccct agggtggagg agagcgttcc tataggtaga ggcacagttt     10260
tatggagctt agggcgcgca gcaagacgta gtgaagagaa attctcgcca acgatatgat     10320
cgctaaaagc aaagtttaaa tacccacatt ctacgatgtt ttcaaggtac actcccgtat     10380
tataaataga aatcgggtac tgccttaatg ttaaataagg gagctcttgg ttggcatttt     10440
ggaaagagtt taccttaaca gaagaggtga gataccttc aaaatagttg tcattccaag     10500
tgcaatcgac acgtgtgggg cctgtatttt tcaacatgaa gttgttgggg aaaatgtcag     10560
caacagtttc ccaactatcg ctgagatggt attctccaga aaaatttaca tgcttatgcg     10620
tgaagcagaa atctccgtgt aggcgatagc gatcatgagc ttctgccata tcgatagcaa     10680
ggcggtgggc ataatagctt ttcatattga agacattctc aggaacctgc ttctgagaac     10740
aatggaggtt gaatcccatg ccgacgccat gcttgaaaaa gctatccaag aaaaatgtcg     10800
aggagaaatg cttcctagaa atcggcgagt agctcatccc caaataggat cccagaaatc     10860
ctcctgttcc tcctcgaaag tttatcggag gcttagggat ctccataggc atgatagaaa     10920
atggaggtaa gaaaagtatc ggaatgcgac acacccttaa tgttgtcttc cctatagaaa     10980
gaagactatc tgaagaatat tccaggtaat ctccggagag gcacaggtct tttttgggac     11040
cctcggaggt agagatatat cccttccgaa tgactatggt ttctggggtt agagtgatca     11100
tagacccccc tagaaaccaa ggatacatcg cgaatcttcc attagtaaga agacaagagt     11160
ctgtatcttc gtaatactct aggtaatcac aaactagggt ttttgcccta tagttcacca     11220
taacattgcc atgtgcgaca agcttcaggc tttgacccac agtattttct acatacactt     11280
tattggcttg tatccgcagg ttgttatgga tattcaatac cccatcttcg atggtcacaa     11340
tcccagaaac actcttaaag tgactaagat aggagttttt ctttttcaca gcctcttgat     11400
gagtcaaagc atcagctgag gaacccataa gaacaaagga agctagaaat aagaagcaac     11460
gtttcataag acgtaggttg gggttactcc acaatttta tgagtaagcc tgcaaggact     11520
gggaaatttt ttgcatctcc ttccgtcatc agttgtatca ataaacggat atcttcggaa     11580
gacttcgagg tggctagtgt ctctagaata tccaacatga gcttcgtacg gctttctggg     11640
gtgacctgat aacgtagata gggcatgctg ggatggggtc tttggttttc cgtgtccaca     11700
aataacaagg tttcctgaat tagctttttt gcataatcat ggagagaacg tttttttca      11760
ggatctttgg tgagattata aatagcaaga tctgcatagg cgcggatgat aggttctcca     11820
ggaagcttcg cagcttggaa aagtagatct aaggcttcct gatgtgaggt gtgacttaaa     11880
aaagaaatcg cagtagtggc aagctgagtt ttctgactcg ccaaaagctt ataaatacag     11940
gggaggtaag cttctttagg taggcggaag agaaacgtaa ggatctgctc ttcaagacct     12000
cgggttgtgg agagcaacct ttccctctcc tggggatctt gagggactat gatgttcacc     12060
cgcttccaat tttgtaaagt acgcccctta gagaaactca aggctagagt ctcattataa     12120
tgtggttgga caagcctttc ggtaatgtat tccagtagtt taggggtgtc acaccctaac     12180
tctaagagag ctaaagctac attcaacttg gcttcgctgt tcttagtttt taggaatatc     12240
ggcagggcaa tcggaatccc tatctcagag ggtagatgcc gtaaggcata cagggctcga     12300
ggccgctcct caagtgcttg ctttttttatc acgggaagag cgtcctcttc tttccccaaa     12360
gcaattaaag cttgagctgc tgctaaagtg acatccacat caggcttctg caattgcttt     12420
tttatattgt agtagctctg accatcctta agcttcccta aagcataaag aatagcttct     12480
tgatcttgag gagacgcact cgttagcaaa ttcctaagtg tcggaagaaa gcgtttttgt     12540
tggtattctc cgatctgcaa agctgtggca ctccgaatcg cgcttttctt ggcagctaag     12600
agatcccgaa tataagcatc agattcttca gtctccaagc gtaggaatat tgccgcagat     12660
aggcattgga tttcttcggg aagcttatga atgaaagaat gtagatgatc aatgacttta     12720
gtgttcttca aattagcaag tctataggcg gcttctaagc ggatgacagg atagggagat     12780
gctaaagctt taaacagtaa gtcgtcagaa gttttcccaa gatgtcctga gactgccgat     12840
aaaaccagta gctgctgcag ggggtctgca gtttccatag cttgggagag cacgtccaag     12900
gcttctgaag atcccgccag gcctgctcca atgatggtgc tttttctagt ttgcggatct     12960
gaggagtgga tgctttgctt gagatagtct tctccgattt ttcttaaaac gaagaagtca     13020
tgatcaccgt aggcatctag agcttccaga tatgttgcta aggcctgctg tgtagattgc     13080
gtacttatat aaaggatctt atgacctaca gactcaggga atttagcaac aagagaaatg     13140
ggaagactac acaataaaag tccaaagaga gttagatgga atagtcccat agatcgatgt     13200
tcaactcctc tagcaagtat ttcaatgttt ggatagggag accttgaaca ttataaacac     13260
atccatggac ctttttcaaa atcaagccac catggcaaac gtcataagcg ccacaattat     13320
ttaatgttcc tacagtgtcg atataagact ctatgcggtg atcaggaatc atagtaagtg     13380
aaatctgaga agtctctgac cctgtgagga gttttccctt atgtaatacg gcaatactcg     13440
tgaccacatc atgcgtctga ttcctcaagg tctttaacat ctggatagcg tctgctttgt     13500
```

```
cttgaggttt tgtgaaaata cggccatcgt aagaaacaat agtatcgcca gtgaggataa     13560
tacagtcaca aggcgaatgt agctcagaaa ctgcataggc cttttgtgcg gcaagttctt     13620
gtgtataggc tataggatcc ccagagtagc tgactttact ctcatcaaaa tttgaaggaa     13680
tgacagtaaa gggaacacga aatttttcta aaataaattt tcttcttggc gaagaagacc     13740
ctaaaactaa aggaagggac atagaataaa agctcctcgt gttagataca ttacaacaat     13800
tgcttatgac ctgcagtata gtctaccata gttccatcga agaatgtaat cttatcttta     13860
tcaaagatca ataacttcgt agcacaatct tgaatcagtc ctctgtcgtg agagacaaaa     13920
atcgctgtgc ccttatagtc attgatagcc caagaaagag cagacacaga ctctaagtct     13980
aagtggttgt tcgcttcatc aaggataagg acattatggt tttctagcat catccccgcc     14040
atgagaagac gagctgtttc tcctccagat aatgcttgga tttgcttgaa agcatcatcg     14100
cctccaaaaa gcattttccc taacacactg cggatttctt gatcgttaat tccggttttg     14160
cgattgcgta gccactcaaa tagcgtttct tgaccacaat cagctagaac atcgctgtgg     14220
ttttgaggaa aatatgaaca gatagcttga tggcctaact tgatacttcc tgaagaagga     14280
gcctcaacac ctgcaagtaa cttcattaat gtagttttac ccaatccatt gttcccgata     14340
ataccaagct tgtctccttg ataaatctct aaagaaaaag gatggattac ctgatgatcc     14400
ccataatcct ttgtaatcgc ttctaaagac aaaacgactt tccctgagga tttgtcagat     14460
agggggaaac gaatgtaagg acgttggata ttggattttt ttaattcttg tggctgaagc     14520
ttcttaatct ctcttaatcg agactgcact tgactcgctc gtgatcccgc accaaattta     14580
gcaacaaatt ccttaagctg agaaattttc ttttccttag atttgatgtc ggccttttct     14640
tgctcgcgag acgcggtttt catctctacc atatcgtcat agtttccagg gtagataatg     14700
atcgtgtcgt aatcaatgtc agcaatgtga gtcgtaattg tatttaagaa atgacggtcg     14760
tgactgacta caatgacagt gccttcataa tcttttaaaa agtttcccag ccaattaatg     14820
gaatagaggt ccaagtggtt tgttggctca tcaagaagaa gtgcttcggg gtgaccaaag     14880
agagcctggc aaagaagaac tcgaaattgt aggtctatgg gaatcatagc cattttctta     14940
tcaaacatct cattggggat gccaatgcct gtgaggagtt cttcggcttc tgaatctgct     15000
cggtacccat tttcctcgcc gatgatctct tcaatttcac caagctccat tccaatggcg     15060
tcagtaaatt cttgtagata gagattatca cggcgttgta aagcttccca aagacgagta     15120
tttcccataa tgacacaatc taagactgtt gtgtcgtgaa agctatcgat attttgacgc     15180
aggatcccca ctttttagg taaggaaatc gaacctcttg taggttctat cattcccata     15240
atgattttta aaagggtgga ctttcctgcg ccgttaggac cagtaagacc gtagcagttc     15300
ccggggttga aaacgacgga aacatcatcg aataaaattc gagtgcctaa agatttgcca     15360
attttatcta atactatgct catagcagac agcataacaa agtgctgctt agagtacaag     15420
agctttgccc tgttctctta ggcatgggga tgggcttctt ggtgggtctg ttttttaac      15480
tttacagaga cttgcgtata gaccgttgtt gtctctaaag aactatgacc aagaagtgct     15540
tggattgttt ttaaatccat accactctct agccaatggg tggctatagt gtgacggatt     15600
gtatgggggg tgatgtgccc tgaaagtcca gaacgtcgaa gatattcttg aaaacttctg     15660
tcaatagatc gtgttgaaat gcgcctccca aagcgattga gaaagatggc ttgaggatcc     15720
ttttccaaac gctttctatc cggatggttc aggtagattt ggatccattg tatggcattc     15780
gatgtcacgg gaataatcct ttctttttc cctttcccac ggatgcgaat cagatgagta     15840
ctcaaatcaa agtcctgttt attaacagcg acaatctcac taatcctcaa acccgaacta     15900
tagaacagct ccatgagaca gcgatcacga agtccgtgat atttagaaat gtcaggagtc     15960
gccatcagca cttcaacttg cgcataggtc atcggggaag gcagctcctt aggaagacga     16020
ggtccgtgga tagtttccgc aggattttcc aaaagaatct tttgaataac acagtaatgg     16080
gcaaagcttt taatggaaga gaggcaacgc ttaattgttc tcttagcttt gccattttct     16140
atcagtttcg cgatgtacat gcgtacatgc tctttggtga ataaggaaaa aggaagttca     16200
gagactttgc gcttctctgt ggctaactgt aaaggagaag aaggagcgag gttaccacgt     16260
tcctctaaaa aaattttcaa tccattaaga tctagacaat aatttcttaa tgtatgcgga     16320
gaggcacttt ttaccatttt caaatagtct aagaacgaat agatagaggc aatcataact     16380
tctctttacc ttacaataaa gatcgtaaaa agacttcctc ttagctttag gaaggctagc     16440
ttcttact                                                             16448
//
```

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 101768

Fulltext Availability:
Detailed Description

Detailed Description
... G)
Campylobacterjejuni NCTC 11 168 Y17167 tuf
Campylobacterjejuni NCTC 11 168 CJ11168X2 tuf (EF-G)
Chlamydia pneumoniae **CWL029** AE001592 tuf
Chlamydia pneumoniae **CWL029** AE001639 tuf (EF-G)
Chlamydia trachomatis M74221 tuf
Chlamydia trachomatis D/UW-3/CX AE001317 tuf (EF-G)
Chlamydia trachomatis D/UW-3/CX...81-176 U03121 recA
Campylobacterjejuni NCTC 11 168 AL139079 recA
Chlamydia trachomatis L2 U16739 recA
Chlamydia trachomatis D/UW-3/CX AE001335 recA
Chlamydophila pneumoniae **CWL029** AE001658 recA
Chloroflexus aurantiacus J-1041 AF037259 recA
Clostridium acetobutylicum M94057 recA
Clostridium perfringens 13...

1/3,KWIC/14 (Item 10 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00778694
ISOPRENOID BIOSYNTHESIS
BIOSYNTHESE D'ISOPRENOIDES
Patent Applicant/Inventor:
BACHER Adelbert, Konigsbergerstr. 74, D-85748 Garching, DE, DE (Residence), DE (Nationality)
ZENK Meinhart, Carl-von-Ossietzky-Str. 11, D-06114 Halle/Saale, DE, DE (Residence), DE (Nationality)
EISENREICH Wolfgang, Romerhofweg 51a, D-85748 Garching, DE, DE (Residence), DE (Nationality), (Designated only for: US)
FELLERMEIER Monika, Halserspitzstr. 12, D-81673 Munchen, DE, DE (Residence), DE (Nationality), (Designated only for: US)
FISCHER Markus, Ruppertstr. 10, D-80337 Munchen, DE, DE (Residence), DE (Nationality), (Designated only for: US)
HECHT Stefan, Engelhofstr. 6, D-85386 Dietersheim, DE, DE (Residence), DE (Nationality), (Designated only for: US)
HERZ Stefan, Clemensstrasse 12, D-80803 Munchen, DE, DE (Residence), DE (Nationality), (Designated only for: US)
KIS Klaus, Reutberger Strasse 16, D-81371 Munchen, DE, DE (Residence), DE (Nationality), (Designated only for: US)
LUTTGEN Holger, Schleissheimer Strasse 13, D-85748 Garching, DE, DE (Residence), DE (Nationality), (Designated only for: US)
ROHDICH Felix, Moosburger Strasse 16, D-85406 Zolling, DE, DE (Residence), DE (Nationality), (Designated only for: US)
SAGNER Silvia, Hess Strasse 12, D-81673 Munchen, DE, DE (Residence), DE (Nationality), (Designated only for: US)
SCHUHR Christoph A, Zugspitzweg 22, D-85748 Garching, DE, DE (Residence), DE (Nationality), (Designated only for: US)
WUNGSINTAWEEKUL Juraithip, Reischlweg 8A, D-80939 Munchen, DE, DE (Residence), TH (Nationality), (Designated only for: US)
Legal Representative:
WACHTERSHAUSER Gunter, Tal 29, D-80331 Munchen, DE
Patent and Priority Information (Country, Number, Date):
Patent: WO 200111055 A1 20010215 (WO 0111055)

YSTEM:OS - DIALOG OneSearch
File 155:MEDLINE(R) 1966-2002/Sep W5
*File 155: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.
File 349:PCT FULLTEXT 1983-2002/UB=20021003,UT=20020926
(c) 2002 WIPO/Univentio
File 5:Biosis Previews(R) 1969-2002/Oct W1
(c) 2002 BIOSIS
*File 5: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.
File 73:EMBASE 1974-2002/Oct W1
(c) 2002 Elsevier Science B.V.
*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

Set	Items	Description

Cost is in DialUnits
?ds

Set	Items	Description
S1	24	CWL029 (10N) CHLAMYDI?
S2	16	RD (unique items)

?t s1/3,kwic/5-16

1/3,KWIC/5 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00841553 **Image available**
CHLAMYDIA TRANSMEMBRANE PROTEIN AS ANTIGEN, CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE $I(CHLAMYDIA) ET FRAGMENTS D'ADN CORRESPONDANTS, ET LEUR UTILISATION
Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA , CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy Street West, Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200175114 A2-A3 20011011 (WO 0175114)
Application: WO 2001CA462 20010404 (PCT/WO CA0100462)
Priority Application: US 2000194477 20000404
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 18024

Fulltext Availability:
Detailed Description

Detailed Description
... pCACPNM643 containing the transmembrane protein gene.
The myosin heavy chain homolog gene was amplified
from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by
polymerase chain reaction (PCR) using a 51 primer
(

1/3,KWIC/6 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00841552 **Image available**
CHLAMYDIA MYOSIN HEAVY CHAIN HOMOLOG AS ANTIGEN, CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE CHLAMYDIA, FRAGMENTS CORRESPONDANTS D'ADN, ET LEURS UTILISATIONS
Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA , CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy St. W., Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200175113 A2-A3 20011011 (WO 0175113)
Application: WO 2001CA461 20010404 (PCT/WO CA0100461)
Priority Application: US 2000194475 20000404
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 18028

Fulltext Availability:
Detailed Description

Detailed Description
... the myosin heavy chain homolog
gene.
The myosin heavy chain homolog gene was amplified
from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by
polymerase chain reaction (PCR) using a 5' primer
(5f ATAAGAATGCGGCCGCCACCATGCATGACGCACTTCTAAGCA 3f; SEQ ID No...

1/3,KWIC/7 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00841551 **Image available**
CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENE <I>CHLAMYDIA</I>, FRAGMENTS D'ADN CORRESPONDANTS, ET LEURS UTILISATIONS

Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA , CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy St. W., Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspen Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200175112 A2-A3 20011011 (WO 0175112)
Application: WO 2001CA460 20010404 (PCT/WO CA0100460)
Priority Application: US 2000194472 20000404
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 18044

Fulltext Availability:
Detailed Description

Detailed Description
... pCACPNM653 containing the glutamate binding protein gene.
The glutamate binding protein gene was amplified from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 51 primer (51 ATAAGAATGCGGCCGCCACCATGAAGATAAAATTTTCTTGGAAGG 3'; SEQ ID No...

1/3,KWIC/8 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00841550 **Image available**
CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE CHLAMYDIA ET FRAGMENTS D'ADN CORRESPONDANTS, ET UTILISATIONS DE CEUX-CI
Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA , CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy St. W., Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspen Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):
Patent: WO 200175111 A2-A3 20011011 (WO 0175111)
Application: WO 2001CA456 20010404 (PCT/WO CA0100456)
Priority Application: US 2000194471 20000404
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 18039

Fulltext Availability:
Detailed Description

Detailed Description
... pCACPNM760 containing the myosin heavy chain gene.

The myosin heavy chain gene was amplified from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 51 primer (5' ATAAGAATGCGGCCGCCACCATGGCAAAATATCCACTAGAGCC 31; SEQ ID No...

1/3,KWIC/9 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00841504 **Image available**
CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE CHLAMYDIA, FRAGMENTS D'ADN CORRESPONDANTS, ET UTILISATIONS DESDITS FRAGMENTS
Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA , CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy Street W., Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200174863 A2-A3 20011011 (WO 0174863)
Application: WO 2001CA455 20010404 (PCT/WO CA0100455)
Priority Application: US 2000194464 20000404
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 18015

Fulltext Availability:
Detailed Description

Detailed Description
... pCACPNM209 containing the ATP-binding cassette gene.

The ATP-binding cassette gene was amplified from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 51 primer 51 ATAAGAATGCGGCCGCCACCATGCGCAAGATATCAGTGGGAATC 3'; SEQ ID No...

1/3,KWIC/10 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00812849 **Image available**
CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE CHLAMYDIA, FRAGMENTS D'ADN CORRESPONDANTS ET UTILISATIONS DE CEUX-CI
Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill L4B 3C2, CA, CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy Street W., Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
MORROW Joy D (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street, Station D, P.O. Box 2999, Ottawa, Ontario K1P 5Y6, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200146226 A2-A3 20010628 (WO 0146226)
Application: WO 2000CA1536 20001220 (PCT/WO CA0001536)
Priority Application: US 99171538 19991222
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 16495

Fulltext Availability:
Detailed Description

Detailed Description
... plasmid
vector pCABkO99 containing the membrane ATPase gene.
The membrane ATPase gene was amplified from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 51 primer (5f ATAAGAATGCGGCCGCCACCATGCAAACAATCTACACAAAAATAAC 3r; SEQ ID No...

1/3,KWIC/11 (Item 7 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00812848 **Image available**
CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES ANTI-CHLAMYDIA, FRAGMENTS D'ADN CORRESPONDANTS ET LEURS UTILISATIONS
Patent Applicant/Assignee:
AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA , CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy Street West, Aurora, Ontario L4G 2L6, CA, CA (Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
MORROW Joy D (et al) (agent), Smart & Biggar, P.O. Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200146225 A2-A3 20010628 (WO 0146225)
Application: WO 2000CA1535 20001220 (PCT/WO CA0001535)
Priority Application: US 99171539 19991222
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 16393

Fulltext Availability:
Detailed Description

Detailed Description
... pCABk319 containing the outer membrane protein gene.

The outer membrane protein gene was amplified from **Chlamydia** pneumoniae genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 5' primer (5f ATAAGAATGCGGCCGCCACCATGAAAAAATTATTATTTTCTAC 3f; SEQ ID No...

1/3,KWIC/12 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00810074
COMPLEMENTARY PEPTIDE LIGANDS GENERATED FROM MICROBIAL GENOME SEQUENCES
LIGANDS PEPTIDIQUES COMPLEMENTAIRES PRODUITS A PARTIR DE SEQUENCES GENOMIQUES MICROBIENNES
Patent Applicant/Assignee:
PROTEOM LIMITED, Babraham Hall, Babraham, Cambridge CB2 4AT, GB, GB (Residence), GB (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
ROBERTS Gareth Wyn, The Grange, Church Street, Great Shelford, Cambridge CB2 5EL, GB, GB (Residence), GB (Nationality), (Designated only for: US)
HEAL Jonathan Richard, 21 Fingal Street, Greenwich, London SE10 0JL, GB, GB (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
DAVIES Jonathan Mark (agent), Reddie & Grose, 16 Theobalds Road, London

WC1X 8PL, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200142278 A2-A3 20010614 (WO 0142278)
Application: WO 2000GB4778 20001213 (PCT/WO GB0004778)
Priority Application: GB 9929466 19991213
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 10697

Fulltext Availability:
Detailed Description

Detailed Description
... et al., Nature,
Genorne Size (Mb) 1.44 s/SplashPage.html 390: 580-586 (1997)
Chlamydia pneurnoniae **CWL029** B Acute respiratory infections and
http:Hchlarnydia- Kalman et al., Nat Genorne Size (Mb) 1...

1/3,KWIC/13 (Item 9 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00791380 **Image available**
HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE PROBES AND PRIMERS FOR DETECTION OF MICROORGANISMS
GENES A FORT POUVOIR DE CONSERVATION ET LEUR UTILISATION POUR PRODUIRE DES SONDES D'ACIDE NUCLEIQUE SPECIFIQUES A L'ESPECE, SPECIFIQUES AU GENE, SPECIFIQUES A LA FAMILLE, SPECIFIQUES AU GROUPE ET UNIVERSELLES ET DES SONDES D'AMPLIFICATION, EN VUE DE DETECTER ET D'IDENTIFIER RAPIDEMENT DES MICRO-ORGANISMES ALGAIRES, ARCHEOBA
Patent Applicant/Assignee:
INFECTIO DIAGNOSTIC (I D I) INC, 2050 Rene-Levesque Blvd., West, 4th Floor, Sainte-Foy, Quebec G1V 2K8, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
BERGERON Michel G, 1145 des Erables, Quebec, Quebec G2K 1T8, CA, CA (Residence), CA (Nationality), (Designated only for: US)
BOISSINOT Maurice, 109 Jean Bruchesi, St-Augustin-de-Desmaures, Quebec G3A 2N2, CA, CA (Residence), CA (Nationality), (Designated only for: US)
HULETSKY Ann, 1231 des Pins Avenue, Sillery, Quebec G1S 4J3, CA, CA (Residence), CA (Nationality), (Designated only for: US)
MENARD Christian, 1174 du Pont, St-Lambert-de-Levis, Quebec G0S 2W0, CA, CA (Residence), CA (Nationality), (Designated only for: US)
OUELLETTE Marc, 1035 de Ploermel, Sillery, Quebec G1S 3S1, CA, CA (Residence), CA (Nationality), (Designated only for: US)
PICARD Francois J, 1245 de la Sapiniere, Cap-Rouge, Quebec G1Y 1A1, CA, CA (Residence), CA (Nationality), (Designated only for: US)
ROY Paul H, 28 Charles Garnier, Loretteville, Quebec G2A 2X8, CA, CA (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
DUBUC Jean H (et al) (agent), Goudreau Gage Dubuc, The Stock Exchange Tower, 800 Place Victoria, Suite 3400, P.O. Box 242, Montreal, Quebec H4Z 1E9, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200123604 A2-A3 20010405 (WO 0123604)
Application: WO 2000CA1150 20000928 (PCT/WO CA0001150)
Priority Application: CA 2283458 19990928; CA 2307010 20000519
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

Application: WO 2000EP7548 20000803 (PCT/WO EP0007548)
Priority Application: DE 19936663 19990804; DE 19945175 19990921; DE 19945174 19990921; DE 19948887 19991011; DE 19953309 19991105; DE 10020996 20000428
Designated States: AE AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 40376

Fulltext Availability:
Detailed Description

Detailed Description
... trachomatis D/UW-3/CX C.T. gb AE00 1 320, 3348-4007 gb AE
Chlamydia pneumoniae **CWL029** c. P. gb AE001642, 7155-7790 gb AE
Thermotoga maritima T. M. gb AE001792, 3951...AE000713, 10428-11234
Chlamydia trachomatis D/UW-3/CX C.T. gb AE001352, 9579-10445
Chlamydia pneumoniae **CWL029** c. P. gb AE001675, 2514-3406
Thermotoga maritima T. M. gb AE001791.1, 13364-14179...

1/3,KWIC/15 (Item 11 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00757848
NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS FOR PROKARYOTIC AND EUKARYOTIC ORGANISMS
DOSAGES DIAGNOSTIQUES D'ACIDES NUCLEIQUES PAR SONDE POUR ORGANISMES PROCARYOTES ET EUCARYOTES
Patent Applicant/Assignee:
ENTERPRISE IRELAND (trading as BioResearch Ireland), Glasnevin, Dublin 9, IE, IE (Residence), IE (Nationality), (For all designated states except: US)
NATIONAL UNIVERSITY OF IRELAND GALWAY, University Road, Galway, IE, IE (Residence), IE (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
BARRY Thomas Gerard, The Quay, Kinvara, County Galway, IE, IE (Residence), IE (Nationality), (Designated only for: US)
SMITH Terence James, 18 Hawthorne Place, Clybaun Road, Galway, IE, IE (Residence), IE (Nationality), (Designated only for: US)
Legal Representative:
ANNE RYAN & CO (agent), 60 Northumberland Road, Ballsbridge, Dublin 4, IE
,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200070086 A1 20001123 (WO 0070086)
Application: WO 2000IE66 20000515 (PCT/WO IE0000066)
Priority Application: WO 99IE43 19990514
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 23736

Fulltext Availability:
Detailed Description

Claims

Detailed Description
... ID NO: 159
Bordetella bronchiseptica tmRNA
GGGGCCGAUCCGGAUUCGACGUGGGUCAUGAAACAGCUCAAGGC
20 AUGCCGAGCACCAGUAAGCUCGUTJAAUCCACUGGAACACUACAA
ACGCCAACGACGAGCGUUUCGCUCUCGCCGCUUAAGCGGUGAGC
CGCUGCACUGAUCUGUCCUUGGGUCACGCGGGGGAA
SEQ ID NO: 160
Chlamydiapneumoniae (**CWL029**), ssrA
GGGGGTGTATAGGTTTCGACTTGAAAATGAAGTGTTAATTGCAT
GCGGAGGGCGTTGGCTGGCCTCCTAAAAAGCCAACAAAACAATA
AATGCCGAACCTAAGGCTGAATGCGAAATTATTAGCTTGTTTGA
CTCAGTAGAGGAAAGACTAGCTGCTTAATTAGCAAAAGTTGTTA
GCTAGATAATCTCTAGGTAACCCGGTATCTGCGAGCTCCACCAG
AGGCTTGCAAAATACCGTCATTTATCTGGTTGGAACTTACTTTCT
CTAATTCTCAAGGAAGTTCGTTCGAGATTTTTGAGAGTCATTGGC
TGCTATAGAGGCTTCTAGCTAAGGGAGTCCAATGTAAACAATTC
10 TAGAAGATAAGCATGTAGAGGTTAGCAGGGAGTTTGTCAAGGAC
GAGAGTTCGAGTCTCTCCACCTCCACCA SEQ ID NO: 161
Chlamydiapneumoniae (**CWL029**) tmRNA
GGGGGUGUAUAGGUUUCGACUUGAAAAUGAAGUGUUAAUUGC
15 AUGCGGAGGGCGUUGGCUGGCCUCCUAAAAAGCCAACAAAACA
AUAAAUGCCGAACCUAAGGCUGAAUGCGAAAUUAUUAGCUUG
UUUGACUCAGUAGAGGAAAGACUAGCUGCUUAAUUAGCAAAA
GUUGUUAGCUAGAUAAUCUCUAGGUAACCCGGUAUCUGCGAG
CUCCACCAGAGGCUUGCAAAAUACCGUCAUUUAUCUGGUUGGA
20 ACUUACUUUCUCUAAUUCUCAAGGAAGUUCGUUCGAGAUUUU
UGAGAGUCAUUGGCUGCUAUAGAGGCUUCUAGCUAAGGGAGU
CCAAUGUAAACAAUUCUAGAAGAUAAGCAUGUAGAGGUUAGC
AGGGAGUUUGUCAAGGACGAGAGUUCGAGUCUCUCCACCUCCA
CCA SEQ...

Claim
... ucucgccgcu 120
uaagcgguga gccgcugcac ugaucugucc uugggucacg cgggggaa 168
<210> 161
<211> 426
<212> DNA
<213> **Chlamydia** pneumoniae (**CWL029**)
<400> 161
gggggtgtat aggtttcgac ttgaaaatga agtgttaatt gcatgcggag ggcgttggct 60
ggcctcctaa aaagccaaca aaacaataaa tgccgaacct aaggctgaat gcgaaattat...
agaggttagc agggagtttg tcaaggacga gagttcgagt ctctccacct 420
ccacca 426
<210> 162
<211> 426
<212> RNA
<213> **Chlamydia** pneumoniae (**CWL029**)
<400> 162
ggggguguau agguuucgac uugaaaauga aguguuaauu gcaugcggag ggcguuggcu 60
qgccuccuaa aaagccaaca aaacaauaaa ugccgaaccu aaggcugaau gcgaaauuau...

1/3,KWIC/16 (Item 12 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00733372
MEDICAMENT
MEDICAMENT
Patent Applicant/Assignee:
NEUTEC PHARMA PLC, St. James's Court, Brown Street, Manchester, Cheshire M2 2JF, GB, GB (Residence), GB (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
BURNIE James Peter, 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY, GB, GB (Residence), GB (Nationality), (Designated only for: US)

MATTHEWS Ruth Christine, 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY, GB, GB (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
MCNEIGHT & LAWRENCE, Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS, GB
Patent and Priority Information (Country, Number, Date):
Patent: WO 200046359 A2 20000810 (WO 0046359)
Application: WO 2000GB237 20000128 (PCT/WO GB0000237)
Priority Application: GB 992555 19990205
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 7984

Fulltext Availability:
Detailed Description

Detailed Description
... the present invention and the amino acid sequence it encodes are already known from the **Chlamydia** Genome Project (C. pneumoniae **CWL029** /CPnO8O9), as is an apparent C. trachomatis homologue (CT578). However, therapeutic and diagnostic uses for...
?logoff hold
10oct02 14:57:56 User228206 Session D1873.4
$0.01 0.002 DialUnits File155
$0.01 Estimated cost File155
$1.80 0.378 DialUnits File349
$19.20 12 Type(s) in Format 3
$19.20 12 Types
$21.00 Estimated cost File349
$0.01 0.002 DialUnits File5
$0.01 Estimated cost File5
$0.02 0.002 DialUnits File73
$0.02 Estimated cost File73
OneSearch, 4 files, 0.384 DialUnits FileOS
$0.21 TELNET
$21.25 Estimated cost this search
$21.25 Estimated total session cost 0.384 DialUnits

RESULT 2
AAY34620
ID AAY34620 standard; Protein; 348 AA.
XX
AC AAY34620;
XX
DT 13-SEP-1999 (first entry)
XX
DE Chlamydia pneumoniae lipoprotein sequence.
XX
KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;
KW vaccine; neutralising epitope.
XX
OS Chlamydia pneumoniae.
XX
PN WO9927105-A2.
XX
PD 03-JUN-1999.
XX
PF 20-NOV-1998; 98WO-IB01890.
XX
PR 04-NOV-1998; 98US-0107078.
PR 21-NOV-1997; 97FR-0014673.
XX
PA (GEST) GENSET.
XX
PI Griffais R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae
XX
PS Page 640; Disclosure; 1912pp; English.
XX
CC AAY34584-Y35879 represent the proteins encoded by all the open reading
CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.
CC C. pneumoniae causes respiratory disease such as pneumonia and
CC bronchitis and is thought to be a contributing factor in heart
CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in
CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae.
XX
SQ Sequence 348 AA;

Query Match 57.6%; Score 327; DB 20; Length 348;
Best Local Similarity 100.0%; Pred. No. 6.7e-302;
Matches 327; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MGLFHLTLFGLLLCSLPISLVAKFPESVGHKILYISTQSTQQALATYLEALDAYGDHDFF 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      21 mglfhltlfglllcslpislvakfpesvghkilyistqstqqalatylealdaygdhdff 80

Qy      61 VLRKIGEDYLKQSIHSSDPQTRKSTIIGAGLAGSSEALDVLSQAMETADPLQQLLVLSAV 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      81 vlrkigedylkqsihssdpqtrkstiigaglagssealdvlsqametadplqqllvlsav 140

Qy     121 SGHLGKTSDDLLFKALASPYPVIRLEAAYRLANLKNTKVIDHLHSFIHKLPEEIQCLSAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     141 sghlgktsddllfkalaspypvirleaayrlanlkntkvidhlhsfihklpeeiqclsaa 200

Qy     181 IFLRLETEESDAYIRDLLAAKKSAIRSATALQIGEYQQKRFLPTLRNLLTSASPQDQEAI 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     201 iflrleteesdayirdllaakksairsatalqigeyqqkrflptlrnlltsaspqdqeai 260

Qy     241 LYALGKLKDGQSYYNIKKQLQKPDVDVTLAAAQALIALGKEEDALPVIKKQALEERPRAL 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     261 lyalgklkdgqsyynikkqlqkpdvdvtlaaaqalialgkeedalpvikkqaleerpral 320

Qy     301 YALRHLPSEIGIPIALPIFLKTKNSEA 327
           ||||||||||||||||||||||||||
Db     321 yalrhlpseigipialpiflktknsea 347
```

RESULT 3

```
ile 411:DIALINDEX(R)

DIALINDEX(R)
   (c) 2002 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
?sf allscience
   You have 278 files in your file list.
   (To see banners, use SHOW FILES command)
?s chlamyd?/ti and vaccin?/ti

Your SELECT statement is:
   s chlamyd?/ti and vaccin?/ti

          Items   File
          -----   ----
             84     5: Biosis Previews(R)_1969-2002/Oct W1
              1     6: NTIS_1964-2002/Oct W2
              8     9: Business & Industry(R)_Jul/1994-2002/Oct 14
             38    10: AGRICOLA_70-2002/Oct
             38    16: Gale Group PROMT(R)_1990-2002/Oct 14
              7    18: Gale Group F&S Index(R)_1988-2002/Oct 14
              2    19: Chem.Industry Notes_1974-2002/ISS 200242
             10    20: Dialog Global Reporter_1997-2002/Oct 15
             59    34: SciSearch(R) Cited Ref Sci_1990-2002/Oct W2
              4    35: Dissertation Abs Online_1861-2002/Sep
              6    42: Pharmaceuticl News Idx_1974-2002/Oct W1
             78    50: CAB Abstracts_1972-2002/Sep
             30    65: Inside Conferences_1993-2002/Oct W2
             21    71: ELSEVIER BIOBASE_1994-2002/Oct W1
             56    73: EMBASE_1974-2002/Oct W1
              1    74: Int.Pharm.Abs._1970-2002/Sep
              3    98: General Sci Abs/Full-Text_1984-2002/Sep
              3    99: Wilson Appl. Sci & Tech Abs_1983-2002/Sep
      Examined  50 files
>>>Term "TI" is not defined in file 107 and is ignored
             13   107: Adis R&D Insight_1986-2002/Oct W1
             11   111: TGG Natl.Newspaper Index(SM)_1979-2002/Oct 11
>>>Term "TI" is not defined in file 115 and is ignored
              4   115: Research Centers & Services_1994-2002/Jul
>>>Term "TI" is not defined in file 124 and is ignored
              1   124: CLAIMS/REFERENCE 2001/2002Q1
>>>Term "TI" is not defined in file 128 and is ignored
             19   128: PHARMAPROJECTS_1980-2002/Oct W1
             10   129: PHIND(Archival)_1980-2002/Oct W1
              2   135: NewsRx Weekly Reports_1995-2002/Oct W1
             12   143: Biol. & Agric. Index_1983-2002/Sep
             50   144: Pascal_1973-2002/Oct W2
             13   148: Gale Group Trade & Industry DB_1976-2002/Oct 15
              7   149: TGG Health&Wellness DB(SM)_1976-2002/Oct W1
             74   155: MEDLINE(R)_1966-2002/Oct W1
              3   156: ToxFile_1965-2002/Oct W2
              3   160: Gale Group PROMT(R)_1972-1989
             11   162: CAB Health_1983-2002/Sep
>>>Term "TI" is not defined in file 167 and is ignored
              1   167: Medical Device Register (R)_1999
              1   172: EMBASE Alert_2002/Oct W2
              1   174: Pharm-line(R)_1978-2002/Oct W1
              3   180: Federal Register_1985-2002/Oct 11
              2   185: Zoological Record Online(R)_1978-2002/Sep
>>>Term "TI" is not defined in file 189 and is ignored
             13   189: NDA Pipeline: New Drugs_1991-2002/Aug
             24   203: AGRIS_1974-2002/May
      Examined 100 files
              4   266: FEDRIP_2002/Jul
              9   285: BioBusiness(R)_1985-1998/Aug W1
>>>Term "TI" is not defined in file 286 and is ignored
             36   286: Biocommerce Abs.& Dir._1981-2002/Sep B2
```

```
                2   315: ChemEng & Biotec Abs_1970-2002/Sep
                6   319: Chem Bus NewsBase_1984-2002/Oct 15
               18   340: CLAIMS(R)/US Patent_1950-02/Oct 10
               47   342: Derwent Patents Citation Indx_1978-01/200225
                4   344: Chinese Patents Abs_Aug 1985-2002/Oct
               39   345: Inpadoc/Fam.& Legal Stat_1968-2002/UD=200240
                1   347: JAPIO_Oct 1976-2002/Jun(Updated 021004)
               17   348: EUROPEAN PATENTS_1978-2002/Oct W01
               18   349: PCT FULLTEXT_1979-2002/UB=20021010,UT=20021003
               96   357: Derwent Biotech Res.__1982-2002/JUNE W1
        Examined 150 files
                2   358: Current BioTech Abs_1983-2002/Sep
                1   369: New Scientist_1994-2002/Sep W3
                1   371: French Patents_1961-2002/BOPI 200209
>>>Term "TI" is not defined in file 375 and is ignored
                1   375: Derwent Drug Registry_1997-2002/Sep W4
>>>Term "TI" is not defined in file 390 and is ignored
               40   390: Beilstein Online_
               61   399: CA SEARCH(R)_1967-2002/UD=13716
                2   429: Adis Newsletters(Archive)_1982-2002/Oct 15
               24   434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
              983   440: Current Contents Search(R)_1990-2002/Oct 14
                5   441: ESPICOM Pharm&Med DEVICE NEWS_2002/Oct W2
               14   445: IMS R&D Focus_1991-2002/Oct W1
>>>Term "TI" is not defined in file 453 and is ignored
                6   453: Drugs of the Future_1990-2002/Aug
                6   455: Drug News & Perspectives_1992-2002/Sep
                8   459: Daily Essentials (Archival)_1996-2002/Sep W4
                2   484: Periodical Abs Plustext_1986-2002/Oct W1
        Examined 200 files
>>>Term "TI" is not defined in file 590 and is ignored
                1   590: KOMPASS Western Europe_2002/FEB
                2   610: Business Wire_1999-2002/Oct 15
                3   613: PR Newswire_1999-2002/Oct 15
                8   621: Gale Group New Prod.Annou.(R)_1985-2002/Oct 11
                1   635: Business Dateline(R)_1985-2002/Oct 12
               29   636: Gale Group Newsletter DB(TM)_1987-2002/Oct 14
                1   637: Journal of Commerce_1986-2002/Oct 10
                9   649: Gale Group Newswire ASAP(TM)_2002/Oct 10
               15   654: US PAT.FULL._1976-2002/Oct 08
        Examined 250 files
                3   761: Datamonitor Market Res._1992-2002/Oct
                1   764: BCC Market Research_1989-2002/Oct
                1   765: Frost & Sullivan_1992-1999/Apr
                5   767: Frost & Sullivan Market Eng_2002/Sep
                1   810: Business Wire_1986-1999/Feb 28
                4   813: PR Newswire_1987-1999/Apr 30

   83 files have one or more items; file list includes 278 files.
   One or more terms were invalid in 90 files.

?save temp
Temp SearchSave "TD611" stored
?rf
Your last SELECT statement was:
   S CHLAMYD?/TI AND VACCIN?/TI

R
```

SYSTEM:OS - DIALOG OneSearch
File 155:MEDLINE(R) 1966-2002/Oct W1
*File 155: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.
File 10:AGRICOLA 70-2002/Oct
(c) format only 2002 The Dialog Corporation
File 65:Inside Conferences 1993-2002/Oct W2
(c) 2002 BLDSC all rts. reserv.
File 203:AGRIS 1974-2002/May
Dist by NAL, Intl Copr. All rights reserved
File 636:Gale Group Newsletter DB(TM) 1987-2002/Oct 14
(c) 2002 The Gale Group
File 654:US PAT.FULL. 1976-2002/Oct 08
(c) FORMAT ONLY 2002 THE DIALOG CORP.
*File 654: is redesigned with new search and display features. See HELP NEWS654 for details. Reassignments current through Jun. 7, 2002.
File 348:EUROPEAN PATENTS 1978-2002/Oct W01
(c) 2002 European Patent Office
File 35:Dissertation Abs Online 1861-2002/Sep
(c) 2002 ProQuest Info&Learning
File 344:Chinese Patents Abs Aug 1985-2002/Oct
(c) 2002 European Patent Office
File 347:JAPIO Oct 1976-2002/Jun(Updated 021004)
(c) 2002 JPO & JAPIO
*File 347: JAPIO data problems with year 2000 records are now fixed. Alerts have been run. See HELP NEWS 347 for details.
File 371:French Patents 1961-2002/BOPI 200209
(c) 2002 INPI. All rts. reserv.
*File 371: This file is not currently updating. The last update is 200209.

Set	Items	Description

Cost is in DialUnits
?t s2/9/1 2 3 5 6 8 11 12 15 16 19 36 37

2/9/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13556958 22051209 PMID: 12056482
Protection evaluation against Chlamydophila **abortus challenge by DNA** vaccination **with a dnaK-encoding plasmid in pregnant and non-pregnant mice.**
Hechard Celine; Grepinet Olivier; Rodolakis Annie
Unite de Pathologie Infectieuse et Immunologie, INRA. Centre de Tours, Nouzilly, France.
Veterinary research (France) May-Jun 2002, 33 (3) p313-26, ISSN 0928-4249 Journal Code: 9309551
Document type: Evaluation Studies; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Mice were intramuscularly immunized with a dnaK-encoding DNA plasmid. The protective effect of DNA immunization against Chlamydophila abortus infection was studied in pregnant and non-pregnant mice models. In non-pregnant mice, the dnaK vaccine induced a specific humoral response with the predominant IgG2a isotype, which **failed** to have in vitro neutralizing properties. No delayed-type hypersensitivity reaction was observed and the spleens of dnaK vaccinated-mice were not protected against C. abortus challenge. In pregnant mice, the dnaK vaccine induced a non-specific **partial** protection from abortion. This may be due to the immunogenic properties of the CpG motifs of bacterial DNA present in the vaccinal plasmid backbone. Nevertheless, spleens of dnaK vaccinated-pregnant mice were not protected.
Tags: Animal; Female; Pregnancy; Support, Non-U.S. Gov't
Descriptors: *Chlamydophila--immunology--IM; *Chlamydophila Infections --veterinary--VE; *Heat-Shock Proteins 70--genetics--GE; *Vaccines, DNA --administration and dosage--AD; Antibodies, Bacterial--biosynthesis--BI;

Chlamydophila--genetics--GE; Chlamydophila Infections --prevention and control--PC; Disease Models, Animal; Heat-Shock Proteins 70--immunology--IM ; Immunoglobulin G--biosynthesis--BI; Immunoglobulin G--blood--BL; Injections, Intramuscular--veterinary--VE; Mice; Plasmids; Recombinant Proteins--genetics--GE; Recombinant Proteins--immunology--IM; Spleen --immunology--IM; Spleen--microbiology--MI; Vaccines, DNA--immunology--IM

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Heat-Shock Proteins 70); 0 (Immunoglobulin G); 0 (Plasmids); 0 (Recombinant Proteins); 0 (Vaccines, DNA); 0 (dnaK protein)

Record Date Created: 20020611

2/9/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

13493579 21906483 PMID: 11908999

Chlamydia vaccines **: strategies and status.**

Igietseme Joseph U; Black Carolyn M; Caldwell Harlan D

Microbiology & Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, Georgia 30310, USA. igietsj@msm.edu

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (New Zealand) 2002, 16 (1) p19-35, ISSN 1173-8804

Journal Code: 9705305

Contract/Grant No.: AI 41231; AI; NIAID; GM 08248; GM; NIGMS; RR 03034; RR; NCRR

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The ultimate goal of current chlamydial vaccine efforts is to utilise either conventional or modern vaccinology approaches to produce a suitable immunisation regimen capable of inducing a sterilising, long-lived heterotypic protective immunity at mucosal sites of infection to curb the severe morbidity and worldwide prevalence of chlamydial infections. This lofty goal poses tremendous challenges that include the need to clearly define the relevant effectors mediating immunity, the antigens responsible for inducing these effectors, the anti-chlamydial action(s) of effectors, and establishment of the most effective method of vaccine delivery. Tackling these challenges is further compounded by the biological complexity of chlamydia, the existence of multiple serovariants, the capacity to induce both protective and deleterious immune effectors, and the occurrence of asymptomatic and persistent infections. Thus, novel molecular, immunological and genetic approaches are urgently needed to extend the frontiers of current knowledge, and develop new paradigms to guide the production of an effective vaccine regimen. Progress made in the last 15 years has culminated in various paradigm shifts in the approaches to designing chlamydial vaccines. The dawn of the current immunological paradigm for antichlamydial vaccine design has its antecedence in the recognition that chlamydial immunity is mediated primarily by a T helper type1 (Th1) response, requiring the induction and recruitment of specific T cells into the mucosal microenvironment. Additionally, the ancillary role of humoral immune response in complementing the Th1-driven protective immunity, through ensuring adequate memory and optimal Th1 response during a reinfection, has been recognised. With continued progress in chlamydial genomics and proteomics, select chlamydial proteins, including structural, membrane and secretory proteins, are being targeted as potential subunit vaccine candidates. However, the development of an effective adjuvant, delivery vehicle or system for a potential subunit vaccine is still an elusive objective in these efforts. Promising delivery vehicles include DNA and virus vectors, bacterial ghosts and dendritic cells. Finally, a vaccine still represents the best approach to protect the greatest number of people against the ocular, pulmonary and genital diseases caused by chlamydial infections. Therefore, considering the urgency and the enormity of these challenges, a **partially** protective vaccine preventing certain severe sequelae would constitute an acceptable short-term goal to control Chlamydia. However, more research efforts and support are needed to achieve the worthy goal of protecting a significant number of the world's population from the devastating consequences of chlamydial invasion of the

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS

Chlamydia pneumoniae is an intracellularly growing bacterium that causes respiratory infections and is strongly associated with atherosclerosis. Antibodies against C. pneumoniae are frequently encountered in the adult population, indicating past exposure to the micro-organism. Immunity to reinfection is, however, only **partial** and does not prevent development of sequelae. Infections caused by and associated with C. pneumoniae are a major cause of morbidity and mortality world wide. Development of a vaccine capable of protecting against infections due to C. pneumoniae and their sequelae would prevent up to 10% of community-acquired pneumonias in adults and add a new dimension to the prevention of atherosclerosis and coronary heart disease. (64 Refs.)

Tags: Human; Support, Non-U.S. Gov't

Descriptors: *Bacterial Vaccines; *Chlamydia Infections--prevention and control--PC; *Chlamydophila pneumoniae--immunology--IM; Adult; Arteriosclerosis--microbiology--MI; Arteriosclerosis --prevention and control--PC; Chlamydia Infections--immunology--IM; Coronary Disease --microbiology--MI; Coronary Disease--prevention and control--PC; Respiratory Tract Infections--microbiology--MI; Respiratory Tract Infections--prevention and control--PC

CAS Registry No.: 0 (Bacterial Vaccines)

Record Date Created: 20000211

2/9/6 (Item 6 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

10203051 99171732 PMID: 10073724

Vaccination **of mice with DNA plasmids coding for the** Chlamydia **trachomatis major outer membrane protein elicits an immune response but** fails **to protect against a genital challenge.**

Pal S; Barnhart K M; Wei Q; Abai A M; Peterson E M; de la Maza L M

Department of Pathology, Medical Sciences I, University of California, Irvine 92697-4800, USA.

Vaccine (ENGLAND) Feb 5 1999, 17 (5) p459-65, ISSN 0264-410X Journal Code: 8406899

Contract/Grant No.: AI-30499; AI; NIAID; AI-32248; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

A DNA plasmid encoding the gene of the major outer membrane protein (MOMP) of the Chlamydia trachomatis mouse pneumonitis (MoPn) serovar and three plasmids containing the variable domains (VD) of the MOMP were constructed. Female mice were inoculated with the plasmids and 60 days later were challenged in the genital tract with C. trachomatis. Six weeks after challenge female mice were caged with male mice and the course of the mating followed. Mice immunized with the MOMP plasmids mounted weak humoral and cell mediated immune responses. However, following the genital challenge no significant differences in vaginal shedding were observed between the groups immunized with the MOMP and control plasmids. In addition, the fertility rates were similar in the experimental and negative control groups. In conclusion, vaccination with DNA plasmids encoding the MOMP elicited a modest immune response but did not protect against infection or disease.

Tags: Animal; Female; Male; Pregnancy; Support, U.S. Gov't, P.H.S.

Descriptors: *Bacterial Outer Membrane Proteins--immunology--IM; *Bacterial Vaccines--immunology--IM; *Chlamydia Infections--prevention and control--PC; *Chlamydia trachomatis--immunology--IM; *Genital Diseases, Female--prevention and control--PC; *Plasmids--immunology--IM; *Vaccines, DNA--immunology--IM; Antibodies, Bacterial--blood--BL; Bacterial Outer Membrane Proteins--genetics--GE; Genetic Vectors; Mice; Mice, Inbred Strains; Vaccination

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Vaccines); 0 (Genetic Vectors); 0

human mucosal epithelia. (210 Refs.)
Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Descriptors: *Bacterial Vaccines--therapeutic use--TU; *Chlamydia --immunology--IM; *Chlamydia Infections--drug therapy--DT; *Chlamydia Infections--prevention and control--PC; *Technology, Pharmaceutical--trends --TD; Bacterial Vaccines--administration and dosage--AD; Bacterial Vaccines--chemical synthesis--CS; Bacterial Vaccines--immunology--IM; Chlamydia Infections--immunology--IM; Drug Delivery Systems--methods--MT; Drug Delivery Systems--trends--TD; Technology, Pharmaceutical--methods--MT
CAS Registry No.: 0 (Bacterial Vaccines)
Record Date Created: 20020322

2/9/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11035453 20580045 PMID: 11137265
Immunity to Chlamydia **pneumoniae induced by** vaccination **with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2).**
Penttila T; Vuola J M; Puurula V; Anttila M; Sarvas M; Rautonen N; Makela P H; Puolakkainen M
Department of Virology, POB 21, Haartman Institute, University of Helsinki, FIN-00014, Helsinki, Finland. tulla.penttila@helsinki.fi
Vaccine (ENGLAND) Dec 8 2000, 19 (9-10) p1256-65, ISSN 0264-410X Journal Code: 8406899
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Immune responses induced by intramuscular DNA immunization with Chlamydia pneumoniae genes coding for the major outer membrane protein (MOMP), cysteine-rich outer membrane protein 2 (Omp2) or the heat shock protein 60 (Hsp60) were studied. BALB/c mice were vaccinated intramuscularly three times at 3-week intervals and challenged intranasally 2 weeks after the last injection. Immunization with pmomp or phsp60 showed 1.2-1.5 log reduction in the mean lung bacterial counts after the challenge. Specific antibodies were detected only in sera of the mice immunized with pomp2 and phsp60. Although immunization with pomp2 resulted in a strong serum antibody response against Omp2 protein, it **failed** to protect the mice. Immunization with any of the three vaccines did not reduce the severity of histologically assessed pneumonia, but resulted in significantly higher lymphoid reaction in the lung indicating immunological memory.
Tags: Animal; Female; Support, Non-U.S. Gov't
Descriptors: *Bacterial Outer Membrane Proteins--genetics--GE; *Bacterial Vaccines--immunology--IM; *Chaperonin 60--genetics--GE; *Chlamydophila pneumoniae--immunology--IM; *Vaccines, DNA--immunology--IM; Antibodies, Bacterial--blood--BL; Bacterial Outer Membrane Proteins--immunology--IM; COS Cells; Chaperonin 60--immunology--IM; Lymphocyte Transformation; Mice; Mice, Inbred BALB C; Vaccination
CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Vaccines); 0 (Chaperonin 60); 0 (Vaccines, DNA); 0 (major outer membrane protein, C. pneumoniae)
Record Date Created: 20010118

2/9/5 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10573200 20111561 PMID: 10646092
Vaccination **against infections by** Chlamydia **pneumoniae.**
Puolakkainen M; Makela P H
Haartman Institute, Department of Virology, University of Helsinki, Finland. mirja.puolakkainen@helsinki.fi
Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie (FRANCE) Nov 1999, 322 (11) p973-8, ISSN 0764-4469 Journal Code: 8503078
Document type: Journal Article; Review; Review, Tutorial

```
SYSTEM:OS  - DIALOG OneSearch
  File 440:Current Contents Search(R)  1990-2002/Oct 10
        (c) 2002 Inst for Sci Info
  File 345:Inpadoc/Fam.& Legal Stat  1968-2002/UD=200239
        (c) 2002 EPO

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?ds

Set     Items   Description
S1          5   AU=GRIFFAIS ? (100N) CHLAMYD?
?t s1/3/5

 1/3/5     (Item 2 from file: 345)
DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat
(c) 2002 EPO. All rts. reserv.

15163549
Basic Patent (No,Kind,Date): CA 2307846 AA 19990603   <No. of Patents: 007>
  CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF
      AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND
      TREATMENT OF INFECTION (English; French)
Patent Assignee: GENSET SA (FR)
Author (Inventor): GRIFFAIS REMY (FR); ZAGURSKY ROBERT J (US); METCALF
     BENJAMIN J (US); PEEK JOEL A (US); SANKARAN BANUMATHI (US); HOISETH
    SUSAN K (US); FLETCHER LEAH D (US)
IPC:  *C12N-015/31;  C07K-019/00;  A01K-067/027; A61K-039/118; C07K-016/12;
    C07K-014/295; G01N-033/53; C12N-015/62; C12Q-001/68
CA Abstract No: *131(03)028638M;
Derwent WPI Acc No: *C 99-357842;
Language of Document: English
Patent Family:
    Patent No    Kind  Date      Applic No   Kind  Date
    AU 9911702     A1  19990615    AU 9911702     A   19981120
    BR 9814878     A   20001003    BR 98U14878    A   19981120
    CA 2307846     AA  19990603    CA 2307846     A   19981120  (BASIC)
    CN 1279717     T   20010110    CN 98811378    A   19981120
    EP 1032674     A2  20000906    EP 98954662    A   19981120
    WO 9927105     A2  19990603    WO 98IB1890    A   19981120
    WO 9927105     A3  19991111    WO 98IB1890    A   19981120
Priority Data (No,Kind,Date):
    FR 9714673 A  19971121
    WO 98IB1890 W  19981120
    US 107078 P  19981104
?logoff hold
       10oct02 15:24:15 User228206 Session D1873.11
            $0.69    0.040 DialUnits File440
     $0.69  Estimated cost File440
            $0.58    0.121 DialUnits File345
              $10.55  1 Type(s) in Format  3
           $10.55  1 Types
    $11.13  Estimated cost File345
            OneSearch, 2 files,  0.161 DialUnits FileOS
     $0.21  TELNET
    $12.03  Estimated cost this search
    $12.03  Estimated total session cost   0.161 DialUnits
```

10/02 BP US-Pat Derwent Biosis Medline

u

(Plasmids); 0 (Vaccines, DNA); 146409-23-6 (major outer membrane protein, Chlamydia trachomatis)
Record Date Created: 19990507

2/9/8 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08733973 96088055 PMID: 8525685
Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine **in a murine model of** Chlamydia **trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against** chlamydial **genital tract infection.**
Su H; Parnell M; Caldwell H D
Laboratory of Intracellular Parasites, NIAID, Rocky Mountain Laboratories, Hamilton, MT 59840, USA.
Vaccine (ENGLAND) Aug 1995, 13 (11) p1023-32, ISSN 0264-410X Journal Code: 8406899
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
The protective efficacy of an alum-adsorbed, parenterally administered synthetic oligopeptide immunogen corresponding to antigenically common T-helper and neutralizing B-cell epitopes of the Chlamydia trachomatis major outer membrane protein was studied in a murine model of chlamydial genital tract infection. Mice produced high levels of anti-chlamydial serum IgG neutralizing antibodies following subcutaneous immunization with the alum-adsorbed oligopeptide. Lower but detectable levels of chlamydial specific IgG antibodies were found in vaginal washes. IgG1 was the predominant isotype present in sera and vaginal washes. Chlamydial-specific IgA was not present in either the sera or vaginal washes of immunized mice. Vaccinated and control mice were challenged intravaginally or intrauterinally with low, medium, or high doses of C. trachomatis serovar D challenge inocula. Protection was assessed by performing quantitative chlamydial cervico-vaginal cultures over the course of the infection period. There were no statistically significant differences between groups of immunized and control mice in either colonization, shedding, or duration of infection. These findings demonstrate that parenteral immunization with the oligopeptide (serum-neutralizing antibodies) is **ineffective** in preventing chlamydial genital tract infection. It is possible, since chlamydial infection is restricted to the genital tract mucosae, that a more accurate evaluation of the oligopeptide vaccine potential will require local rather than systemic immunization.
Tags: Animal; Female
Descriptors: *Antibodies, Bacterial--biosynthesis--BI; *Bacterial Outer Membrane Proteins--immunology--IM; *Bacterial Vaccines--immunology--IM; *Chlamydia Infections--prevention and control--PC; *Chlamydia trachomatis --immunology--IM; *Immunoglobulin G--blood--BL; *Vaccines, Synthetic --immunology--IM; *Vaginal Diseases--prevention and control--PC; Administration, Intravaginal; Antibodies, Bacterial--blood--BL; Bacterial Vaccines--administration and dosage--AD; Chlamydia Infections--blood--BL; Immunoglobulin G--biosynthesis--BI; Immunoglobulin Isotypes--analysis--AN; Immunoglobulin Isotypes--blood--BL; Injections, Subcutaneous; Mice; Mice, Inbred A; Neutralization Tests; Oligopeptides--immunology--IM; Uterus; Vaccines, Synthetic--administration and dosage--AD; Vagina--immunology--IM; Vaginal Diseases--blood--BL
CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Vaccines); 0 (Immunoglobulin G); 0 (Immunoglobulin Isotypes); 0 (Oligopeptides); 0 (Vaccines, Synthetic); 146409-23-6 (major outer membrane protein, Chlamydia trachomatis)
Record Date Created: 19960125

2/9/11 (Item 11 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07238784 92180061 PMID: 1796460

The problems of vaccination **against** chlamydial **abortion sheep]**
Zur Problematik der Vakzination gegen den **Chlamydienabort** beim Schaf.
Thiele D
Institut fur Hygiene und Infektionskrankheiten der Tiere, Justus-Liebig-Universitat Giessen.
Tierarztliche Praxis (GERMANY) Dec 1991, 19 (6) p605-7, ISSN 0303-6286 Journal Code: 7501042
Document type: Journal Article; Review; Review, Tutorial ; English Abstract
Languages: GERMAN
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Different vaccines used against chlamydial abortion in sheep are described. Problems associated with insufficient immunity after vaccination are discussed. Reasons for **failure** of certain vaccine preparations are addressed. Finally new developments in vaccine production are introduced which might be useful in solving problems still existing in the prevention of chlamydial abortion in sheep by vaccination. (24 Refs.)
Tags: Animal; Female; Pregnancy
Descriptors: *Abortion, Veterinary--prevention and control--PC; *Bacterial Vaccines; *Chlamydia Infections--veterinary--VE; *Sheep Diseases --prevention and control--PC; *Vaccination--veterinary--VE; Chlamydia --immunology--IM; Chlamydia Infections--prevention and control--PC; Sheep
CAS Registry No.: 0 (Bacterial Vaccines)
Record Date Created: 19920406

2/9/12 (Item 12 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06463504 90170744 PMID: 2407704
Efficacy of a vaccine **to prevent** Chlamydia **- or Campylobacter-induced abortions in ewes.**
Hansen D E; Hedstrom O R; Sonn R J; Snyder S P
College of Veterinary Medicine, Oregon State University, Corvallis 97331-4802.
Journal of the American Veterinary Medical Association (UNITED STATES) Mar 1 1990, 196 (5) p731-4, ISSN 0003-1488 Journal Code: 7503067
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
In a sheep flock, Chlamydia psittaci, Campylobacter fetus, Ca jejuni, and Salmonella dublin caused abortions. A vaccine that contained C psittaci type I from 2 sources: a cow with pneumonia and an aborted ovine fetus, Ca fetus, Ca jejuni, and 4 strains of K99 Escherichia coli was given to 240 ewes before they were bred. All fetuses, placentas, and lambs, that **died** within 36 hours of birth were examined for infectious agents. Of 55 abortions, 30 (55%) were caused by Chlamydia or Campylobacter spp; 25 of the 30 (83%) abortions took place in the nonvaccinated group (n = 240). Forty-five more lambs **survived** in the vaccinated group than in the nonvaccinated group. Abortion rates for Chlamydia and Campylobacter spp (2.1 vs 10.4% in vaccinated and nonvaccinated groups, respectively) were significantly different (P = 0.003). Abortion rates for S dublin were not significantly different between groups. The Salmonella epizootic was controlled quickly by sanitation and treatment procedures. The vaccine was at least 80% efficacious against Chlamydia and Campylobacter spp and appeared to be protective.
Tags: Animal; Female; Pregnancy
Descriptors: *Abortion, Veterinary--prevention and control--PC; *Bacterial Vaccines; *Campylobacter Infections--veterinary--VE; *Ornithosis --veterinary--VE; *Sheep Diseases--prevention and control--PC; Campylobacter Infections--prevention and control--PC; Campylobacter fetus --immunology--IM; Chlamydophila psittaci--immunology--IM; Escherichia coli --immunology--IM; Ornithosis--prevention and control--PC; Sheep; Vaccination--veterinary--VE
CAS Registry No.: 0 (Bacterial Vaccines)

Record Date Created: 19900405

2/9/15 (Item 1 from file: 65)
DIALOG(R)File 65:Inside Conferences

03011062 INSIDE CONFERENCE ITEM ID: CN031896828
Detection of Cd4+ T-Cells in the Genital Tract of Mice Vaccinated **with Formulated RMOMP that Confers** Partial **Protection Against** Chlamydial **Infertility**
Maisonneuve, J.; Charlier, C.; Friede, M.; Abarca-Quinones, J.
CONFERENCE: European Society for Chlamydia Research-Meeting; 3rd
PROCEEDINGS-EUROPEAN SOCIETY FOR CHLAMYDIA RESEARCH, 1996; NO 3 P: 473
Uppsala, ESCR, 1996
LANGUAGE: English DOCUMENT TYPE: Conference Extended abstracts
CONFERENCE EDITOR(S): Stary, A.
CONFERENCE SPONSOR: European Society for Chlamydia Research
Austrian Society for Dermatology and Venerology Study Group for STD and Dermatological Microbiology
CONFERENCE LOCATION: Vienna
CONFERENCE DATE: Sep 1996 (199609) (199609)

BRITISH LIBRARY ITEM LOCATION: 6699.453000
DESCRIPTORS: ESCR; chlamydia research; dermatological microbiology

2/9/16 (Item 2 from file: 65)
DIALOG(R)File 65:Inside Conferences

01962028 INSIDE CONFERENCE ITEM ID: CN020438360
Intramuscular Immunization with a DNA Vaccine **Produces** Partial **Immunity to** Chlamydia **trachomatis Infection**
Zhang, D.-J.; Yang, X.; Shen, C.; Berry, J.
CONFERENCE: Modern approaches to the control of infectious diseases-Annual meeting; 14th
VACCINES, 1997 P: 113-118
Cold Spring Harbor Laboratory Press, 1997
ISSN: 0899-4056 ISBN: 0879695161
LANGUAGE: English DOCUMENT TYPE: Conference Papers
CONFERENCE EDITOR(S): Brown, F.
CONFERENCE LOCATION: Cold Spring Harbor, NY
CONFERENCE DATE: Sep 1996 (199609) (199609)

BRITISH LIBRARY ITEM LOCATION: 9138.650000
NOTE:
Also known as Vaccines 97
DESCRIPTORS: infectious diseases; vaccines

2/9/19 (Item 3 from file: 636)
DIALOG(R)File 636:Gale Group Newsletter DB(TM)

03983264 Supplier Number: 53053370 (THIS IS THE FULLTEXT)
Chlamydia Vaccine **Nose Is Best Site for** Chlamydia Vaccine .
Vaccine Weekly, pNA
Sept 28, 1998
ISSN: 1074-2921
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 502
TEXT:
The path to a chlamydia vaccine goes through the nose.
Animal studies show that Chlamydia trachomatis antigens administered by the intranasal route elicit the kind of immunity known to protect against chlamydia infection and disease.
"Intranasal immunization is a potential delivery route of choice in

the development of a vaccine against Chlamydia," concluded Joseph U. Igietseme of Morehouse School of Medicine, Atlanta, Georgia, and colleagues.

Igietseme et al. reported their findings in the journal Infection and Immunity ("Route of Infection that Induces a High Intensity of Gamma Interferon-Secreting T Cells in the Genital Tract Produces Optimal Protection against Chlamydia trachomatis Infection in Mice," Infect Immun, 1998;66(9):4030-5).

Chlamydia trachomatis is a sexually transmitted bacterial infection. **Failure** to diagnose and treat the insidious infection, which can remain asymptomatic for long periods of time, can result in pelvic inflammatory disease, ectopic pregnancy, and/or infertility. There are 4 million cases in the U.S. each year, representing yearly health-care costs of $2.18 billion.

Igietseme et al. noted that a number of animal studies show that immune control of C. trachomatis infection requires T-cell mediated immune responses involving interferon gamma.

They hypothesized that vaccine elicitation of interferon gamma secreting T lymphocytes (ISTLs) in the genital tract would differ depending upon the route of vaccine administration.

The researchers used C. trachomatis elementary bodies (EBs) as a crude vaccine antigen for immunization of female BALB/c mice. They administered the antigen either intranasally, intravaginally, orally, or subcutaneously.

T-cells obtained from the animals' genital tracts were restimulated with chlamydial antigen in vitro and analyzed.

"The results suggested that immunization routes that foster rapid induction of vigorous genital mucosal cell-mediated immune (CMI) effectors (e.g., interferon gamma), the CMI-associated humoral effector, IgG2a, and to some extent secretory IgA produce immunity against chlamydial genital infection," Igietseme et al. reported.

One question unanswered by the study is whether chlamydial immunity induced by intranasal immunization can be long lasting.

"Of particular importance to chlamydial genital infection are the factors that regulate the persistence of immune effectors at the genital mucosal site and so foster long-term genital mucosal immunity," Igietseme et al. wrote. "The natures of such factors are presently unknown, but they will be important for the persistence of ISTLs in the genital mucosae."

The researchers currently are hoping to back-engineer a vaccine antigen by cloning interferon-secreting T lymphocytes from the genital tracts of intranasally immunized mice. It is hoped that these clones may help find the crucial protective chlamydial epitopes.

"The identification, mapping, and characterization of such protective epitopes may furnish valuable reagents for designing an experimental vaccine against Chlamydia," Igietseme et al. suggested.

This study was supported by Public Health Service grants AI41231 and RR03034 from the National Institutes of Health.

The corresponding author for this study is Joseph U. Igietseme, Morehouse School of Medicine, Department of Microbiology and Immunology, 720 Westview Dr., SW, Atlanta, GA 30310. Phone: (404) 752-1596. Fax: (404) 752-1179. Email: less than igietsj@msm.edu greater than .

- by Daniel J. DeNoon, Senior Editor

PUBLISHER NAME: Charles W. Henderson
EVENT NAMES: *310 (Science & research)
GEOGRAPHIC NAMES: *1USA (United States)
PRODUCT NAMES: *2831210 (Vaccines for Human Use)
INDUSTRY NAMES: BUSN (Any type of business); HLTH (Healthcare - Medical and Health)
NAICS CODES: 325412 (Pharmaceutical Preparation Manufacturing)

01743207 ORDER NO: AADAA-I9970077

Development of immune responses in mice to Chlamydia **pneumoniae induced by intramuscular genetic** vaccination

Author: Tharp, Anthony C.
Degree: Ph.D.
Year: 2000
Corporate Source/Institution: Vanderbilt University (0242)
Director: William M. Mitchell
Source: VOLUME 61/04-B OF DISSERTATION ABSTRACTS INTERNATIONAL. PAGE 1889. 89 PAGES
Descriptors: HEALTH SCIENCES, PATHOLOGY ; HEALTH SCIENCES, IMMUNOLOGY
Descriptor Codes: 0571; 0982
ISBN: 0-599-75065-0

italic>Chlamydia pneumoniae</italic>, formerly known as TWAR, is a common respiratory tract pathogen which has been associated with 10 percent of diagnosed pneumoniae cases (1). Moreover, world-wide population studies have shown that <italic> C. pneumoniae</italic> is ubiquitous and that re-infection is common (1). Recently, seroepiderniological and ultrastructural studies have associated this pathogen with atherosclerotic cardiovascular disease (2). Atherosclerosis and its complications (i.e., myocardial infarct, ischemic heart disease, and stroke) account for more than 50 percent of **deaths** in the United States (3). Evidence of <italic>C. pneumoniae</italic> being a risk factor was documented during a five-year follow-up of patients being treated for coronary heart disease (CHD). This study documented elevated sera IgA titers against <italic>C. pneumoniae</italic> lipopolysaccharide (LPS) that correlated with an increased risk for CHD (4). Evidence for <italic>C. pneumoniae </italic>'s role in acute myocardial infarcts was documented with 57 percent of these patients having circulating immune complexes containing Chlamydial antigen (LPS) as compared to 12 percent of controls (5).

Although standard antimicrobial therapy is believed to be effective, <italic> C. pneumoniae</italic> infections are usually silent or mildly symptomatic, and therefore not treated, leading to a chronic, persistent infection (6). No studies have been reported that specifically target chronic <italic>C. pneumoniae</italic> for antibiotic eradication. Excessive costs of antibiotic treatment, the necessity of testing large populations, and the potential for drug-resistant strains to develop with therapy are potential problems with treating this pathogen. However, the potential costs of leaving the organism untreated if leading to atherosclerosis is also enormous. Although there is not an effective vaccine currently, one may be designed to offer protection. In this thesis the hypothesis that genetic DNA vaccination in the mouse model using the major outer membrane protein (MOMP) of <italic>C. pneumoniae</italic> as the cellular expressed antigen, will result in an effective vaccine. Genetic vaccination using a plasmid containing MOMP will be tested with a comparison between unmodulated DNA, enhancement by the method of Hormone Immunomodulated Genetic Vaccination (HIGV), and recombinant MOMP for protective efficacy. Systemic humoral and cellular responses to the vaccine will be measured and correlated with protective efficacy.

2/9/37 (Item 2 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online

01404150 ORDER NO: AADAA-I9510389

EXPRESSION OF THE CHLAMYDIA **PSITTACI MAJOR OUTER MEMBRANE PROTEIN IN ESCHERICHIA COLI: A MODEL FOR TRANSLOCATION AND** VACCINE **DEVELOPMENT**

Author: DASCHER, CHRISTOPHER CARTER
Degree: PH.D.
Year: 1994
Corporate Source/Institution: THE UNIVERSITY OF ROCHESTER (0188)
Supervisor: PATRIK BAVOIL
Source: VOLUME 55/11-B OF DISSERTATION ABSTRACTS INTERNATIONAL. PAGE 4693. 193 PAGES
Descriptors: BIOLOGY, MICROBIOLOGY
Descriptor Codes: 0410

• Chlamydia infections represent a serious ongoing health problem throughout the world. The major outer membrane protein (MOMP) of Chlamydia species is an abundant component of the chlamydial outer membrane and is the target of neutralizing antibodies in infected individuals. The entire omp1 gene encoding MOMP from Chlamydia psittaci strain GPIC has been cloned and expressed in Escherichia coli. A tightly regulated T7 promoter is used to control expression of the protein in E. coli. Upon induction of expression, the precursor MOMP (pre-MOMP) is synthesized in the cell. This is followed by the appearance of a lower molecular weight protein that comigrates with mature MOMP from chlamydial elementary bodies on both one-dimensional SDS-PAGE and two-dimensional gels. MOMP is not detected in surface labeling experiments using several MOMP-specific antibodies. In addition, MOMP expressed in E. coli is not accessible to protease treatment without prior permeabilization of the outer membrane. These data indicate that pre-MOMP is translocated to the periplasmic space and processed but is not surface-exposed in E. coli.

Biochemical and genetic techniques have been used to characterize the chlamydial homolog of Hsp60. Coexpression in E. coli of MOMP or a MOMP-PhoA fusion with Hsp60, or other chaperones, does not alter the level of MOMP translocation. The Hsp60 protein from C. psittaci was purified from isolated organisms. Hsp60 was investigated for the presence of intermolecular complexes with translocated chlamydial proteins. Chlamydial Hsp60 can function in trans to suppress a lethal temperature sensitive mutation of a cytoplasmic protein in E. coli.

Highly purified recombinant MOMP and Omp2, another cysteine-rich chlamydial outer membrane protein, were generated. These proteins were used in immunological studies of protective chlamydial antigens. Only MOMP could prime a protective antibody response in BALB/c mice. C3H/HeJ mice, a strain non-responsive to MOMP, **failed** to elicit protective antibodies using various combinations of recombinant MOMP and Omp2 as immunogens. An attenuated Salmonella typhimurium strain was used to deliver both MOMP and Omp2 by oral immunization but was unsuccessful in eliciting anti chlamydial antibodies.

?t s2/3,kwic/31 32

2/3,KWIC/31 (Item 9 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

3230019 **IMAGE Available

Derwent Accession: 1991-245693

Utility

C/ **Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock** chlamydial **proteins;** DETECTION; VACCINE **AGAINST** CHLAMYDIA **INFECTION**

Inventor: Morrison, Richard P., Hamilton, MT
Caldwell, Harlan D., Hamilton, MT
Assignee: The United State of America as represented by the Department of Health and Human Services (06), Washington, DC
U S of America Health & Human Services (Code: 06814)
Examiner: Moskowitz, Margaret (Art Unit: 186)
Assistant Examiner: Cunninghamn, Thomas
Law Firm: Cushman, Darby & Cushman

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5071962	A	19911210	US 90531317	19900531
Priority				US 90531317	19900531

Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial **proteins**

Description of the Invention:

...C. psittaci (GPIC) genomic DNA isolated from 6X10[sup]10 IFU, was **partially** digested with Sau3A, and sized by electrophoresis on a 0.7% agarose gel (Nano, et...

...50 kD, presumably a truncated version of the 57-kD protein found in

pGP57. A **partial** sequence of the 2.0-kb chlamydial DNA fragment from the E1 subclone was obtained...the manufacturer's suggested procedures (Sequenase, United States Biochemical Corp., Cleveland, Ohio). After obtaining a **partial** DNA sequence from the E1 subclone, sequencing was continued using synthetic oligonucleotide primers (SAM1, Milligen... immune guinea pigs (Watkins, supra). Since a major genus-specific constituent of this extract (LPS) **failed** to induce ocular hypersensitivity, the extract was purified using immunoaffinity chromatography to obtain the 45...organisms, lanes 1 and 5, and the recombinant HypB proteins, lanes 2 and 4, but **failed** to react with the homologous protein found in E. coli. (lane 3...

2/3,KWIC/32 (Item 10 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

2422624
Derwent Accession: 1982-41396E
Utility
EXPIRED
C/ Vaccine **against** chlamydous **infections of farm animals;** INACTIV ED SUSPENS **ION OF CELLS OF EGG YOLKS**
Inventor: Kurbanov, Ildus A., Nauchny gorodok, 1, kv. 6, Kazan, SU
Jusupov, Rasikh K., Nauchny gorodok, 1, kv. 35, Kazan, SU
Borovik, Roman V., ulitsa Lunacharskogo, 37, kv. 9, Serpukhov, Moskovskaya oblast, SU
Gabdulkhaev, Talgat G., Nauchny gorodok, 2, kv. 11, Kazan, SU
Kurbanova, Ilmira A., ulitsa Sibirsky trakt, 8, kv. 47, Kazan, SU
Assignee: Unassigned
UNASSIGNED OR ASSIGNED TO INDIVIDUAL (Code: 68000)
Examiner: Rose, Shep K. (Art Unit: 125)
Law Firm: Burgess, Ryan and Wayne

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 4328208	A	19820504	US 81265559	19810520
Priority				US 81265559	19810520

Vaccine **against** chlamydous **infections of farm animals...**

Description of the Invention:
...3) of the animals are not vaccinized. The control non-vaccinized animals (white mice) have **died** , while pregnant guinea pigs have aborted. The vaccinized white mice **survive** , while vaccinized pregnant guinea pigs give healthy brood...vaccinized heifers after the infection have aborted or brough before time weak, nonvital calves which **died** within three days after calving. In all of them the delay in afterbirth emission...

?logoff hold
15oct02 08:23:17 User228206 Session D1874.5
$0.33 0.104 DialUnits File155
$1.68 8 Type(s) in Format 9
$1.68 8 Types
$2.01 Estimated cost File155
$0.02 0.009 DialUnits File10
$0.02 Estimated cost File10
$0.20 0.052 DialUnits File65
$2.20 2 Type(s) in Format 9
$2.20 2 Types
$2.40 Estimated cost File65
$0.02 0.009 DialUnits File203
$0.02 Estimated cost File203
$0.14 0.026 DialUnits File636
$3.45 1 Type(s) in Format 9
$3.45 1 Types
$3.59 Estimated cost File636

```
          $1.23     0.208 DialUnits File654
             $1.40  2 Type(s) in Format  3
          $1.40  2 Types
    $2.63 Estimated cost File654
          $0.04     0.009 DialUnits File348
    $0.04 Estimated cost File348
          $0.14     0.035 DialUnits File35
             $4.60  2 Type(s) in Format  9
          $4.60  2 Types
    $4.74 Estimated cost File35
          $0.09     0.009 DialUnits File344
    $0.09 Estimated cost File344
          $0.10     0.009 DialUnits File347
    $0.10 Estimated cost File347
          $0.04     0.009 DialUnits File371
    $0.04 Estimated cost File371
          OneSearch, 11 files,  0.477 DialUnits FileOS
    $0.21 TELNET
   $15.89 Estimated cost this search
   $15.89 Estimated total session cost   0.477 DialUnits


### Status: Signed Off. (1 minutes)
```

le 369:New Scientist 1994-2002/Sep W2
(c) 2002 Reed Business Information Ltd.
File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS
*File 370: This file is closed (no updates). Use File 47 for more current information.
File 399:CA SEARCH(R) 1967-2002/UD=13715
(c) 2002 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 442:AMA Journals 1982-2002/Sep B2
(c)2002 Amer Med Assn -FARS/DARS apply
*File 442: UDs have been adjusted to reflect the current months' data. No data is missing.
File 444:New England Journal of Med. 1985-2002/Oct W2
(c) 2002 Mass. Med. Soc.
File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.
*File 467: For information about updating status please see Help News467.

Set Items Description
--- ----- -----------
Cost is in DialUnits
?ds

Set Items Description
S1 24 CWL029 (10N) CHLAMYDI?
S2 16 RD (unique items)
S3 0 AU=GRIFFALIS ? AND CHLAMYD?
S4 0 AU=GRIFFALIS ? AND CHLAMYD?
S5 27 AU=GRIFFAIS ? AND CHLAMYD?
S6 2 S5/1999:2002
S7 25 S5 NOT S6
?t s7/9/1-5

7/9/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09173308 97075916 PMID: 8918239
Choosing highly specific primers for the polymerase chain reaction using the octomer frequency disparity method: application to Chlamydia **trachomatis.**
Chenal V; Souque P; Markovits A; **Griffais R**
Laboratoire des Rickettsiales et des Chlamydiales, Institut Pasteur, Paris, France.
Gene (NETHERLANDS) Oct 17 1996, 176 (1-2) p97-101, ISSN 0378-1119 Journal Code: 7706761
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
The eight-nucleotide sequence (octomer) at the 3' end of PCR primers is important to PCR specificity. We describe a correlation between the specificity of PCR primers used with human DNA and the frequency of the 3' octomer in a human database. We therefore applied a methodology (OFD) based on octomer frequency disparity to identify 16 PCR targets in the chromosome of the intracellular bacterium, **Chlamydia** trachomatis (Ct). In addition, the 16 sets of primers were tested with a standard procedure. All the primer pairs were highly specific for Ct and did not lead to non-specific amplification when used with human DNA. This work shows that the choice of specific PCR primers is possible using a method based on the statistical representativeness of octomers in genomes.
Tags: Human
Descriptors: **Chlamydia** trachomatis--genetics--GE; *DNA Primers; *Polymerase Chain Reaction; Chromosomes, Bacterial; Oligodeoxyribonucleotides; Sensitivity and Specificity

CAS Registry No.: 0 (DNA Primers); 0 (Oligodeoxyribonucleotides)
Record Date Created: 19970107

7/9/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08576774 95336475 PMID: 7612032
Amplification of plasmid and chromosome Chlamydia **DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies.**
Bas S; **Griffais R** ; Kvien T K; Glennas A; Melby K; Vischer T L
Research Laboratory, University Hospital, Geneva, Switzerland.
Arthritis and rheumatism (UNITED STATES) Jul 1995, 38 (7) p1005-13, ISSN 0004-3591 Journal Code: 0370605
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: AIM; INDEX MEDICUS
OBJECTIVE. To investigate the hypothesis that whole bacteria might be found in the joints of patients with **Chlamydia** -associated reactive arthritis. METHODS. The presence of 2 plasmid- and 2 chromosome-specific sequences of **Chlamydia** DNA was investigated by amplification with the polymerase chain reaction, in synovial fluid (SF) samples from 71 patients with various arthropathies. RESULTS. **Chlamydia** DNA was found in SF samples from 22 patients. CONCLUSION. Whole **chlamydiae** are likely present in the SF of patients with **Chlamydia** -associated reactive arthritis.
Tags: Female; Human; Male
Descriptors: Arthritis, Reactive--microbiology--MI; * **Chlamydia** --genetics--GE; * **Chlamydia** Infections--microbiology--MI; *DNA, Bacterial --analysis--AN; *Synovial Fluid--microbiology--MI; Adolescence; Adult; Base Sequence; Blotting, Southern; **Chlamydia** --isolation and purification--IP; Chromosomes, Bacterial--chemistry--CH; DNA, Bacterial--chemistry--CH; DNA, Bacterial--genetics--GE; Gene Amplification; Middle Age; Molecular Sequence Data; Plasmids--genetics--GE; Polymerase Chain Reaction; Sensitivity and Specificity
CAS Registry No.: 0 (DNA, Bacterial); 0 (Plasmids)
Record Date Created: 19950814

7/9/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06667492 90364279 PMID: 2168087
Synthesis of digoxigenin-labelled DNA probe by polymerase chain reaction: application to Epstein-Barr virus and Chlamydia **trachomatis.**
Griffais R ; Andre P M; Thibon M
Laboratoire des Chlamydiales et Rickettsiales, Institut Pasteur, Paris, France.
Research in virology (FRANCE) May-Jun 1990, 141 (3) p331-5, ISSN 0923-2516 Journal Code: 8907469
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Descriptors: **Chlamydia** trachomatis--genetics--GE; *DNA Probes --biosynthesis--BI; *Digoxigenin; *Digoxin; *Herpesvirus 4, Human--genetics --GE; Blotting, Southern; DNA, Bacterial--analysis--AN; DNA, Viral --analysis--AN; Digoxin--analogs and derivatives--AA; Polymerase Chain Reaction
CAS Registry No.: 0 (DNA Probes); 0 (DNA, Bacterial); 0 (DNA, Viral) ; 1672-46-4 (Digoxigenin); 20830-75-5 (Digoxin)
Record Date Created: 19901004

7/9/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

YSTEM:OS - DIALOG OneSearch
File 440:Current Contents Search(R) 1990-2002/Oct 10
(c) 2002 Inst for Sci Info
File 345:Inpadoc/Fam.& Legal Stat 1968-2002/UD=200239
(c) 2002 EPO

Set	Items	Description

Cost is in DialUnits
?ds

Set	Items	Description
S1	5	AU=GRIFFAIS ? (100N) CHLAMYD?

?t s1/3/5

1/3/5 (Item 2 from file: 345)
DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat
(c) 2002 EPO. All rts. reserv.

15163549
Basic Patent (No,Kind,Date): CA 2307846 AA 19990603 <No. of Patents: 007>
CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION (English; French)
Patent Assignee: GENSET SA (FR)
Author (Inventor): GRIFFAIS REMY (FR); ZAGURSKY ROBERT J (US); METCALF BENJAMIN J (US); PEEK JOEL A (US); SANKARAN BANUMATHI (US); HOISETH SUSAN K (US); FLETCHER LEAH D (US)
IPC: *C12N-015/31; C07K-019/00; A01K-067/027; A61K-039/118; C07K-016/12; C07K-014/295; G01N-033/53; C12N-015/62; C12Q-001/68
CA Abstract No: *131(03)028638M;
Derwent WPI Acc No: *C 99-357842;
Language of Document: English
Patent Family:

Patent No	Kind	Date	Applic No	Kind	Date	
AU 9911702	A1	19990615	AU 9911702	A	19981120	
BR 9814878	A	20001003	BR 98U14878	A	19981120	
CA 2307846	AA	19990603	CA 2307846	A	19981120	(BASIC)
CN 1279717	T	20010110	CN 98811378	A	19981120	
EP 1032674	A2	20000906	EP 98954662	A	19981120	
WO 9927105	A2	19990603	WO 98IB1890	A	19981120	
WO 9927105	A3	19991111	WO 98IB1890	A	19981120	

Priority Data (No,Kind,Date):
FR 9714673 A 19971121
WO 98IB1890 W 19981120
US 107078 P 19981104
?logoff hold

06322703 90018831 PMID: 2678327
Detection of Chlamydia **trachomatis by the polymerase chain reaction.**
Griffais R ; Thibon M
Laboratoire des Chlamydiales et Rickettsiales, Institut Pasteur, Paris.
Research in microbiology (FRANCE) Feb 1989, 140 (2) p139-41, ISSN 0923-2508 Journal Code: 8907468
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Tags: Comparative Study; Human
Descriptors: **Chlamydia** trachomatis--isolation and purification--IP; Bacteriological Techniques; **Chlamydia** Infections--diagnosis--DI; **Chlamydia** trachomatis--genetics--GE; Fluorescent Antibody Technique; Polymerase Chain Reaction
Record Date Created: 19891030

7/9/5 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00183025
IMPROVEMENTS RELATED TO TECHNIQUES FOR THE AMPLIFICATION OF NUCLEIC ACID
PERFECTIONNEMENTS APPORTES AUX TECHNIQUES D'AMPLIFICATION D'ACIDE NUCLEIQUE
Patent Applicant/Assignee:
INSTITUT PASTEUR,
GRIFFAIS Remy,
Inventor(s):
GRIFFAIS Remy
Patent and Priority Information (Country, Number, Date):
Patent: WO 9100363 A1 19910110
Application: WO 90FR499 19900703 (PCT/WO FR9000499)
Priority Application: FR 898873 19890703
Designated States: AU BG CA HU JP KR RO SU US
Main International Patent Class: C12Q-001/68
International Patent Class: C12Q-01:48; C12Q-01:70; C07H-21:04
Publication Language: French
Fulltext Word Count: 6460

English Abstract
Improvement relating to techniques for the amplification of nucleic acids, in particular by polymerization chain reaction (PCR). Said process for the detection and/or the identification of a nucleic acid sequence or of a mixture of nucleic acid sequences once the biological sample has been placed in an appropriate solution in order to extract the nucleic acid or acids, includes the following steps: (1) the destruction of the 5' ends of the nucleic acid sequences with double strand which are present in the sample, by bringing said biological sample into contact with an appropriate reaction agent which is active at a temperature of between 37degrees - 42degreesC; (2) the actual amplification by bringing the resulting sample into contact with (1) appropriate reagents, in particular amplification initiators suitable for the amplification of the target sequence or sequences to be detected, in the presence of a heat-resistant polymerase DNA; (3) detection of the specific amplified target sequences.

F

AAY34619

ID AAY34619 standard; Protein; 245 AA.
XX
AC AAY34619;
XX
DT 13-SEP-1999 (first entry)
XX
DE Chlamydia pneumoniae transmembrane protein sequence.
XX
KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;
KW vaccine; neutralising epitope.
XX
OS Chlamydia pneumoniae.
XX
PN WO9927105-A2.
XX
PD 03-JUN-1999.
XX
PF 20-NOV-1998; 98WO-IB01890.
XX
PR 04-NOV-1998; 98US-0107078.
PR 21-NOV-1997; 97FR-0014673.
XX
PA (GEST) GENSET.
XX
PI Griffais R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae
XX
PS Page 639-640; Disclosure; 1912pp; English.
XX
CC AAY34584-Y35879 represent the proteins encoded by all the open reading
CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.
CC C. pneumoniae causes respiratory disease such as pneumonia and
CC bronchitis and is thought to be a contributing factor in heart
CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in
CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae.
XX
SQ Sequence 245 AA;

Query Match 42.4%; Score 241; DB 20; Length 245;
Best Local Similarity 100.0%; Pred. No. 2.3e-220;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    328 KLNVALALLELGCDTPKLLEYITERLVQPHYNETLALSFSKGRTLQNWKRVNIIVPQDPQ 387
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      5 klnvalallelgcdtpklleyiterlvqphynetlalsfskgrtlqnwkrvniivpqdpq 64

Qy    388 ERERLLSTTRGLEEQILTFLFRLPKEAYLPCIYKLLASQKTQLATTAISFLSHTSHQEAL 447
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     65 ererllsttrgleeqiltflfrlpkeaylpciykllasqktqlattaisflshtshqeal 124

Qy    448 DLLFQAAKLPGEPIIRAYADLAIYNLTKDPEKKRSLHDYAKKLIQETLLFVDTENQRPHP 507
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    125 dllfqaaklpgepiirayadlaiynltkdpekkrslhdyakkliqetllfvdtenqrphp 184

Qy    508 SMPYLRYQVTPESRTKLMLDILETLATSKSSEDIRLLIQLMTEGDAKNFPVLAGLLIKIV 567
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    185 smpylryqvtpesrtklmldiletlatskssedirlliqlmtegdaknfpvlagllikiv 244

Qy    568 E 568
          |
Db    245 e 245
```